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ABSTRACT 
 Waldenström’s Macroglobulinemia (WM) is a rare, indolent, non-Hodgkin’s 
lymphoma whose molecular pathology remains poorly understood. This disease is 
characterized by the accumulation of IgM-secreting lymphoplasmacytic cells in the bone 
marrow, and is often histopathologically indistinguishable from marginal zone 
lymphoma, IgM-secreting myeloma, and chronic lymphocytic leukemia with plasmacytic 
differentiation. To better understand the genomic landscape of this disease, whole 
genome sequencing was performed on bone marrow samples from thirty WM patients, 
ten of which were paired with germline tissue. This study identified two genes that are 
frequently mutated in WM: MYD88 and CXCR4. MYD88 was somatically mutated in 
90% of WM samples, which displayed a single nucleotide variant resulting in a leucine to 
proline substitution at position 265. As prev iously demonstrated in activated B-cell 
subtype of diffuse large B-cell lymphoma, this mutation results in constitutive activation 
of the Toll-like receptor pathway and activation of nuclear factor kappa B (NFκB). 
	  	   vii 
Highly sensitive allele specific polymerase chain reaction assays were developed to 
detect MYD88L265P in WM and related hematological malignancies. These studies 
demonstrated that MYD88L265P could be used to aid in the differential diagnosis, response 
assessment, and detection of minimal residual disease in WM. Moreover, MYD88L265P 
was observed in 50% of the precursor condition, IgM monoclonal gammopathy of 
undetermined significance, suggesting that it is an early event in the pathogenesis of 
WM. Blocking MYD88 dimerization or the use of downstream IRAK1/4 kinase 
inhibitors decreased the phosphorylation and nuclear localization of NFκB. Somatic 
mutations in CXCR4 were only found in the regulatory C-terminal tail and were present 
in 29% of WM patients. These mutations were similar or identical to those found in the 
germline of patients with the autosomal dominant disease Warts, 
Hypogammaglobulinemia, Infection, and Myelokathexis (WHIM) syndrome. CXCR4 
somatic WHIM-like mutations were found nearly exclusively in MYD88L265P mutated 
patients. These mutations impaired receptor internalization, increased signaling 
downstream of CXCR4, and instilled resistance to several WM directed therapeutics. 
WM patients who were wild type for both CXCR4 and MYD88 demonstrated inferior 
overall survival. These studies evidence highly recurring somatic events, and provide a 
genomic basis for the molecular pathogenesis of WM. 
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CHAPTER ONE – Aims and Background Information 
Section One – Specific Aims 	   Waldenström’s Macroglobulinemia (WM) is a rare, indolent, non-Hodgkin’s 
lymphoma (NHL) corresponding to the histopathological classification of IgM secreting 
lymphomplasmacytic lymphoma (LPL) by the World Health Organization [1,2]. Since 
the first clinical description of WM by Jan Waldenström in 1944, considerable progress 
has been made in the diagnosis and care of patients, but the underlying molecular 
pathology for WM remains insufficiently understood [3,4]. In addition, marginal zone 
lymphoma (MZL), IgM secreting myeloma, and chronic lymphocytic leukemia with 
plasmacytic differentiation are often histopathologically indistinguishable from WM 
[1,4]. Identification of the genomic events responsible for WM could aid in the 
differential diagnosis of WM, clarify signaling responsible for the growth and survival of 
WM cells, and also provide novel targets for therapeutic intervention. This study 
proposes the use of whole genome sequencing (WGS) to investigate small non-
synonymous coding variants (SNV) in conjunction with copy number alterations (CNA) 
and other structural variant (SV) data to better understand the pathogenetic basis of this 
rare disease. 
 
Specific Aims 
I. Develop a WGS analysis pipeline to identify biologically relevant CNA, SNV, 
and SV variants. Develop additional bioinformatics tools to aid in the assessment 
and interpretation of these findings. 
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II. Identify activating mutations important for WM LPL cell growth and survival.  
 
III. Investigate the relationship of patient genotypes from Specific Aim II to clinical 
presentation, overall survival and response to therapy.  
 
IV. Determine if somatic variants from Specific Aims I and II can be used to 
differentiate WM from related malignancies such as MZL, and IgM multiple 
myeloma. 
 
Section Two – Waldenström’s Macroglobulinemia 
Despite the passage of seventy years since WM disease was first described, genomic 
studies into this disease have lagged compared to other closely related malignancies 
including chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma 
(DLBCL), and multiple myeloma (MM). This is due in part to the relatively low age 
adjusted incidence rate of 3.4 per million among males and 1.7 per million among 
females of WM in the United States of America, which complicates recruitment to 
adequately powered studies [5,6]. The median age of diagnosis for WM is approximately 
60 years, with a median overall survival of 5-10 years. There are indications that overall 
survival is increasing with improved patient care and therapeutics [4,7,8]. At diagnosis, 
patients typically present with significant bone marrow (BM) infiltration by LPL cells 
which contributes to cytopenias. Patients can also exhibit adenopathy and/or 
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splenomegaly in 15% and 10% of cases, respectively [4]. Many of the clinical 
manifestations which can include peripheral neuropathy, elevated serum viscosity, retinal 
hemorrhaging, cryoglobulinemia, cold-agglutinin disease, and light chain amyloidosis are 
related to the significantly increased serum IgM production which usually presents at 
levels that are more than 25 times the upper limit of normal [4,9,10]. Correspondingly, 
patients generally present with hypogammaglobulinemia of the uninvolved 
immunoglobulins with IgA (63%), IgG (58%), or both (49%) falling below the lower 
limit of normal which does not improve with therapy [11]. Low serum IgA and IgG 
levels contribute to recurring sino-bronchial infections in WM patients [4]. 
 
Due to the difficulties associated with serial quantification of BM WM 
lymphoplasmacytic cells (LPC), including the invasiveness of the BM biopsy procedure, 
clinical response assessment relies on changes in serum monoclonal IgM levels [12]. 
Decreases in monoclonal serum IgM of 25%, 50%, 90%, and 100% correspond to minor 
(MR), partial (PR), very good partial (VGPR) and complete responses (CR), respectively. 
Likewise, a greater than 25% increase in serum IgM or significant worsening of WM 
associated clinical features is used to determine disease progression. For extramedullary 
disease, there must be a measurable decrease for determination of a PR, and complete 
resolution to qualify for a VGPR or CR. A negative confirmatory BM biopsy is necessary 
to confirm a CR. The presence of VGPR or CR is associated with longer progression free 
survival [13,14]. Unfortunately, many new targeted therapeutics such as the anti-CD20 
monoclonal antibody rituximab, the mammalian target of rapamycin (MTOR) inhibitor 
	  	  
4 
everolimus, and the proteasome inhibitor bortezominb, can modulate serum IgM levels 
independent of BM disease response [15–17].   
 
There are a number of hematological malignancies that can have clinically similar 
presentations to WM including MM, CLL, and MZL [2,4,18]. Notably, all of these 
entities, including WM, can evolve from monoclonal gammopathy of undetermined 
significance (MGUS) suggesting the possibility of early genetic events or predispositions 
held in common between these B-cell lineage neoplasms [19–21]. In fact, there are 
multiple lines of evidence suggesting the existence of genetic predispositions to WM 
including preliminary genetic linkage studies and that up to a quarter of WM patients 
have a 1st or 2nd degree relative with either WM or related lymphoid malignancy [22–24]. 
A number of epidemiological studies have shown an increased risk for other indolent 
NHL, DLBCL, and CLL in family members of WM patients, and secondary cancers in 
WM patients themselves [25–27]. 
 
Despite evidence for genetic factors in the pathogenesis of WM, little is known about the 
genetics or molecular pathology of this disease. The only previously established genetic 
abnormalities prior to this study were the identification of deletions in chromosome 6q21-
23 in 40%-60% of WM patients, with concordant gains in 6p in 41% of 6q deleted 
patients [23,28,29]. Gains in chromosomes 3q, 4, 18, 8q and Xq as well as losses of 
11q23, 13q14, and 17p have also been described in up to 20% of WM cases [28,30]. As 
6q deletions represent the most recurrent genetic finding, there has been a great deal of 
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interest in identifying the minimally deleted regions and target genes in this locus. Two 
such candidates are TNFAIP3, a negative regulator of nuclear factor kappa B signaling 
(NFκB) and PRDM1, a master regulator of B-cell development [23,31]. The removal of 
an NFκB negative regulator is of particular interest as the activation and translocation of 
NFκB into the nucleus is a crucial event for WM cell survival [32]. This has led to 
speculation that the success of proteasome inhibitor therapy in WM is due in part to 
inhibition of the degradation of negative regulators of NFκB such as inhibitor of kappa B 
(IκB) [32–34]. 
 
Waldenström’s marcroglobulinemia LPCs demonstrate extensive interactions within the 
BM micro-environment as evidenced by MMP8 mediated shedding of CD27 into the 
extra-cellular milieu [35,36]. The solubilized CD27 then binds to the CD70 receptors on 
mast cells that are found admixed in increased numbers with BM LPCs. WM LPC 
released soluble CD27 in turn induces mast cells to express CD154, TNFSF13, and 
TNFSF13B [35,37,38]. These ligands bind to receptors expressed on WM LPC including 
CD40, TNFRSF13B, TNFRSF13C, and TNFRSF17 which have been shown to provide 
growth and survival signaling to WM cells [37,39]. Recent studies have also 
demonstrated the constitutive activation of and subsequent down stream modulation of 
serum IgM secretion by STAT5A and STAT5B in WM patients, most likely in response 
to cytokine signaling [40]. Changes in soluble CD27 secretion also correlate with 
changes in serum IgM levels in WM patients suggesting a possible association with 
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additional micro-environmental interactions or even autocrine secretion of known IgM 
modulating cytokines such as IL6 [35,41,42]. 
 
Section Three – Human Whole Genome Sequencing 
The human genome is approximately three billion base pairs long or six billion when 
counting both alleles. Its sheer size has presented significant obstacles for the 
development of whole genome sequencing of individuals for clinical or research 
purposes. A series of developments in the past two decades, most notably the completion 
of the Human Genome Project, have made whole genome sequencing a valuable and 
practical research tool [43]. The most significant of these is the advent of next generation 
sequencing technologies. While there are a number of proprietary approaches that have 
been well documented, all have relied on the same basic principles [44–46]. High quality 
deoxyribonucleic acid (DNA) is sheared, often by sonication or acoustic shearing, in such 
a way that mean fragment size is known with a tight distribution in length variation. The 
ends of the fragments are repaired and adaptor sequences ligated on the ends. From here, 
the methodologies start to differ, but all involve using these adaptors to attach the short 
fragments to a substrate, locally amplify, and finally use the adaptors as primers to 
sequence the clustered copies generating a short “read”. This is done in a massively 
parallel fashion generating enough of these short reads to cover the genome many times 
over (Figure 1). 
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Figure 1: Assembled short reads 
Next generation sequencing reads mapped to the human reference genome as viewed in the Integrative Genomics 
Viewer (IGV) (Broad Institute, Cambridge, MA). A C/T polymorphism can be observed in the middle of the image. 
 
In this study, Complete Genomics Inc. performed whole genome sequencing using a 
DNA nanoball-based next generation sequencing technology [46]. In brief, the sonicated 
DNA is run through a gel for improved fragment size selection of 400-500 base pairs and 
the ends are ligated with adaptors. These adaptors allow the fragment to circularize into a 
plasmid. Restriction enzymes are then used to cut the plasmid 13bp to the right of the 
adaptor. These ends are ligated with new adaptors that again are used to circularize the 
fragment. This processes is repeated on the other end of the adaptor. A final set of 
restriction enzymes cut 26 base pairs away from the second and third adaptors removing 
the majority of the DNA separating them. The ends are ligated with adaptors and 
circularized to form the final plasmid consisting of two ~ 39 base pair DNA fragments 
that genomically map roughly 400-500 base pairs away from each other with a short 
adaptor sequence inserted 13bp into the middle of each (Illustration 1).  
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Illustration 1: DNA nanoball library construction 
 
This generation of paired reads of known distance and orientation to each other is known 
as mate-pair or paired end library construction and is utilized by many sequencing 
platforms. This plasmid is copied continuously to create a tangle of amplified plasmid 
known as a DNA nanoball. The nanoballs are captured on specialized array. Using the 
adaptors as primers, each nanoball is sequenced by ligation with the resulting florescence 
of each nanoball at each ligation captured by camera.  
 
The next step involved in WGS is to assemble the reads to produce an accurate model of 
the original genome. Advances in computer science and engineering as well as the 
development of computational techniques such as the Burrows-Wheeler compression 
algorithm, have allowed fast accurate mapping of next generation sequencing reads to the 
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human reference genome [47,48]. This works as long as the sequenced genome closely 
matches the reference. Assembling reads with a reference genome on some polymorphic 
sites can cause biasing in the mapping but sequencing genomes without a reference is 
intensive computationally and significantly affects mapping confidence and accuracy. To 
accurately sequence samples with a reference genome, a compromise known as local de 
novo assembly can be applied [49]. Regions that do not sufficiently map to the references 
are independently reassembled without one. Early whole genome de novo assembly with 
Sanger sequencing reads was accomplished by maximizing the overlap between the reads 
to generate a consensus layout sequence. This is a very difficult process computationally, 
made more so when the reads are short such as with next generation sequencing [50,51]. 
This problem has lead to the promotion of an obscure and counter intuitive approach 
involving de Bruijn graphs.  
 
To understand how de Bruijn graphs can be used in de novo assembly it is necessary to 
understand the origins of mathematical networks. There was a famous puzzle in the city 
of Konigsberg. A river cut through the city and bridges were needed to cross to the 
central islands and access either bank as seen in Illustration 2. The puzzle was this: could 
a person start somewhere in Konigsberg and walk across all seven bridges exactly once? 
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Illustration 2: Euler’s solution to the seven bridges of Konigsberg.  
A map of the city of Konigsberg in Euler’s time with the bridges highlighted in green is shown on the left. Realizing 
the path within each landmass did not matter Euler simplified the problem to a network as shown on the right. Map of 
the Konigsberg in the 1700’s acquired from:  "Konigsberg bridges" by Bogdan Giuşcă - Public domain (PD), based on 
the image. Licensed under Creative Commons Attribution-Share Alike 3.0 via Wikimedia Commons - http:// 
commons.wikimedia.org/wiki/File:Konigsberg_bridges.png#mediaviewer/File:Konigsberg_bridges.png 
 
The mathematician, Leonhard Euler, solved this problem by simplifying it [52]. He 
realized that the only thing that mattered was how the bridges connected to each other 
and generated a graph where each vertex (dot) was a land mass and the edges (lines) 
represented the bridges connecting them. The layout of the vertices and edges changes 
nothing, only the connections matter. He reasoned that in order to make such a circuit in 
Konigsberg, one would need to both arrive at and leave a landmass each visit with the 
exception of the starting and finishing locations. Therefore there can be no more than 2 
vertices with an odd number of edges (bridges). Since all of the landmasses in 
Konigsberg had an odd number of bridges connecting them, no such route through the 
city existed. When such a path through a network exists, it is known as a Eulerian path. 
By taking a concrete problem and representing it as an abstract graph, Euler was able to 
use its intrinsic structure to solve a complicated network problem. De Bruijn graphs apply 
these same principles to de novo assembly as shown in Illustration 3 [50]. 
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Illustration 3: De novo assembly with de Bruijn graphs. 
Short reads, such as the one shown in (A) are chopped in to k-meres. K=5 is shown here for simplicity but generally 
they are much longer. Non-unique five-meres are shown in red. The set of unique k-meres are then connected based on 
consensus overlap of 3’ k-1-mere with 5’ k-1-mere of the target k-mere (B). In this case, five-meres are connected if 
their last four base pairs match the first four of a five-mere. Note that k-meres can have more than one connection and 
that unlike the bridges of Konigsberg, they also have a direction. This is our de Bruijn graph. K-meres with only one 
connection can be merged to simplify the graph (C). Unlike the Konigsberg problem, we know this came from a 
continuous stretch of DNA and therefore a Eulerian path exists. This simplifies the assembly processes to a path 
finding algorithm. Following the Eulerian path generates our de novo assembly of the original sequence from the k-
meres (D). 
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While polymorphisms and sequencing errors generate graph structures that can be 
algorithmically identified, like the maximal overlapping consensus that came before it, 
there are a number of potential assembly errors and non-unique solutions. However, due 
to the relative computational, if not conceptual simplicity of the de Bruijn based 
approach, it is now the basis of many modern de novo assemblers [49,53–56]. 
 
Section Four – Whole Genome Sequencing Data Analysis 
Next generation sequencing generates a great deal of data. There are the reads 
themselves, the confidence of the individual base calls in the read, the confidence of their 
mapping to the reference/de novo assembly, information about the relationship between 
the two mate pairs, and data regarding the number of these reads that support a 
sequencing call at every base pair.  All of this information is used to generate a picture of 
the target genome that goes beyond the small sequence polymorphisms detected by the 
assembler.  
 
There are typically enough paired end reads to cover the entire genome multiple times 
over. The number of reads supporting a base pair or a region is referred to as its coverage. 
Since short reads are randomly captured and sequenced, one can calculate the coverage 
mean and standard deviation for consecutive regions of equal length known as windows. 
The larger the window, the tighter the distribution, especially if applying corrections for 
frequency of the strongly binding G and C nucleotides (GC content) and the presence of 
large sequences found in multiple places in the genome known as degenerate regions. 
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These adjustments are less important for somatic detection as both the tumor and 
germline window are subject to the same biasing factors effectively balancing each other 
out. Relative coverage is local coverage normalized to the genome wide mean coverage 
allowing for better comparisons between genomes that may have different mean coverage 
levels. The most common approach to copy number alteration (CNA) analysis is to use 
the gain and loss analysis of DNA (GLAD) algorithm to segment the genome into regions 
of equivalent copy number that are then analyzed by the genomic identification of 
significant targets in cancer (GISTIC) algorithm to determine the significant targets 
within a population cohort [57,58]. These bioinformatics approaches were developed for 
use in array comparative genomic hybridization (aCGH) data and later adapted for next 
generation sequencing approaches. However, small and especially sub-clonal CNA can 
be difficult to identify at the segmentation phase rendering them invisible to GISTIC or 
similar analysis. 
 
The mate-pairs themselves can be used to generate information about the genome. The 
most immediate consequence is that they aid in analysis of degenerate sequences as long 
as one of the mates lands in a non-degenerate region. They also provide a great deal of 
information regarding structural variation (SV). For example, if multiple mate pairs in a 
region have one mate map to chromosome 2 and the other to chromosome 17, then there 
is evidence of a t(2;17) translocation and the region between them can be flagged for 
local de novo assembly.  If they map too close or too far from each other it can be an 
indication of a large deletion or amplification, respectively. Discordant orientation can 
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indicate a local inversion. If the downstream read maps upstream of the first read, that 
can indicate the presence of tandem duplications not present in the reference genome. 
 
In addition to coverage and mate-pair analysis, lesser allele fraction (LAF) can be an 
invaluable for WGS data interpretation. In a typical heterozygous germline autosomal 
polymorphism, there is a 50% chance that a read will support the reference and a 50% 
chance it will support the variant allele. Taking the percentage of reads mapping to all 
such variant alleles should generate a mean of 50% with a normal distribution around the 
mean such as the one observed is Figure 2. 
 
 
 
 
 
 
 
 
 
 
Figure 2: Distribution of reads supporting the variant calls.  
The percentage of reads mapping to variant alleles of high confidence heterozygous polymorphisms from autosomes 
with no CNA were assessed over a whole genome. Bars represent a histogram of frequency. The blue line represents 
the expected normal distribution base on the data.  
 
The LAF corresponds to the percentage of reads supporting the least covered allele. 
While a LAF of ~50% is expected in our example from Figure 2, if a somatic duplication 
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of one allele were to occur, the expected allele distribution would be 33%/66%, 
generating a LAF of 33% throughout the CNA region regardless of which allele was 
amplified. Likewise, somatic variants existing only in a tumor subclone will show a 
lower than expected LAF, but only for the variants unique to the subclone. Copy number 
neutral loss of heterozygosity, also known as acquired uniparental disomy (aUPD) refers 
to cases where an allele from one chromosome is somatically deleted and replaced by a 
copy of the remaining allele. This results in a region where the copy number remains 
unchanged but the region is now homozygous for one allele. When fully clonal, large 
runs of somatic homozygousity in copy number neutral regions can identify aUPDs. With 
sufficient germline contamination in the tumor sample or if the aUPD is not fully clonal, 
the alternate allele can still be called. Even subclonal aUPDs will significantly alter the 
LAF over the whole region. Therefore, in copy number neutral regions, changes in LAF 
can be used alongside loss of heterozygosity to detect aUPDs. 
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CHAPTER TWO: Whole Genome Sequencing of Tumor and Germline DNA from 
Patients with Waldenström’s Macroglobulinemia 
Section One – Introduction 
In order to investigate underlying genetic lesions in WM, thirty patients meeting the 
International Consensus Criteria for WM diagnosis were collected for whole genome 
sequencing [2]. Patients who were either untreated or treated with non-mutagenic agents 
such as monoclonal antibody therapy and had sufficient germline and tumor DNA as 
described in section two, were selected for this study. Tumor DNA from CD19+ BM LPL 
cells was isolated from 30 WM patients, along with matching DNA samples from CD19-
depleted peripheral blood mononuclear cells (PBMC) for use in germline analysis. All 30 
tumor and 10 of the CD19-depleted PBMC samples were submitted for WGS to 
Complete Genomics (Mountain View, CA). Germline DNA from the unpaired samples 
was retained for validation and to confirm somatic status of mutations discovered through 
WGS analysis. 
 
Section Two – Materials and Methods 
Sample Collection and Preparation 
BM aspirates and peripheral blood (PB) samples were collected in heparinized syringes 
from thirty patients with the clinicopathological diagnosis of WM as defined by the 
Second International Workshop on WM [2]. Participants provided informed consent prior 
to sample collection in accordance with the Dana-Farber Cancer Institute Institutional 
Review Board. Relevant clinical characteristics and blood work are presented in Table 1. 
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BM and PBMC were isolated by density gradient centrifugation using Ficoll-Paque 
(Amersham-Pharmacia Biotech, Piscataway, NJ). WM LPC were isolated from BM 
mononuclear cells by CD19+ selection using immunomagnetic MACS micro-beads 
(Miltenyi-Biotech, Auburn, CA). To minimize potential contamination from circulating 
WM LPC, PBMCs were depleted of CD19+ cells using CD19+ MACS micro-beads. 
 
Table 1: Clinical characteristics of the whole genome sequencing WM patient cohort 
 
 
 
 
 
 
 
 1As assessed by light chain restriction analysis 
 
Whole Genome Sequencing 
High molecular weight DNA was extracted using Allprep DNA/RNA mini kit in 
accordance to the manufactures instructions (Qiagen, Valencia, CA). Sample quality and 
quantity were assessed by gel electrophoresis and Picogreen assays (Invitrogen Corp., 
Carlsbad, CA). BM CD19+ as well as CD19-depleted PBMC DNA samples from 30 WM 
patients were collected for analysis and validation. Ten ng of DNA from all 30 BM 
CD19+ as well as 10 of the matching CD19-depleted PBMC samples were sent for mate-
Median Range
Age 62 41-87
Familial WM 9 (30%) NA
Untreated 26 (87%) NA
Gender 24M / 6F NA
Bone Marrow Involvement (%) 65% 5-95%
Clonal B-cells(%)1 96.3 55.5-100
IgM (mg/dL) 3,970 590-6,580
IgMκ/IgMλ monoclonal protein 24/6 NA
IgA (mg/dL) 41 11-516
IgG (mg/dL) 519 215-3,120
Serum B2M (mg/L) 3.55 1.50-12.1
Hematocrit (%) 31.4 24.0-41.5
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pair library construction, and WGS (Complete Genomics). Resulting read sequences were 
aligned to the human reference genome (GRCh37/HG19) with potential variant regions 
subject to local de novo assembly using both Bayesian and de Bruijn graph techniques to 
define a best-fit model with allele specific confidence scores. These scores are based on a 
Phred like scale approximating -10*log(Probability of Error) rounded to the nearest 
integer value. Relative copy number changes were estimated from normalized read 
coverage adjusted for GC content. Heterozygous variant frequency and LAF were 
calculated for all genomes by counting the number of heterozygous variants and the 
percent of total reads mapping to the less covered allele respectively with both averaged 
over a 500Kb window. Acquired uniparental disomy (aUPD) was identified as somatic 
copy-neutral loss of heterozygosity. Other structural variants were inferred from mate 
pair discordant mapping, gap size, and orientation [46,59]. 
 
Whole Genome Sequencing Data Analysis Pipeline 
Somatic SNVs and SV were identified for 10 patient samples by comparing CD19+ BM 
samples to their paired germline PBMC CD19- DNA with cgatools version 1.3 
(cgatools.sourceforge.net). This analysis generated a somatic confidence score 
corresponding to 1 – sensitivity. For all samples, novel variants were identified by 
filtering against dbSNP version 132, the 1,000 genomes project November 2010 release, 
and Complete Genomics’ 46 sample “Diversity Panel” using Annovar [43,46,60,61]. 
Novel results were then annotated against RefSeq and filtered for non-synonymous 
variants [62]. These SNPs were further annotated against dbNSFP for rescaled pre-
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calculated results from the variant impact assessment algorithms SIFT, Polyphen2, and 
Mutation Taster using cut offs scores of ≥ 0.95 for each test to predict for deleterious 
variants [63]. To better distinguish pathogenic from passenger mutations, all variants for 
which scores were available had to meet the damage prediction cut off of at least one of 
the three aforementioned algorithms. Bioinformatic cut offs for called variants were set at 
≥ 50 and ≥ .01 for the allele score and somatic score respectively. As suspected 
pathogenic variants are present in dbSNP, all variants filtered out in this process were 
checked against the dbSNP132 Flagged SNP Database [60]. These analyses, outlined in 
Figure 3 below, lead to a false positive rate in the validated variants of 15%. 
 
Figure 3: Outline of whole genome sequencing analysis pipeline.   
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Somatic discordant mate-pair junctions were identified from the ten-paired samples and 
subsequently organized into structural events using cgatools (cgatools.sourceforge.net). 
Only novel somatic structural events were included in this analysis. Both structural and 
small variant data were visualized using Circos graphing software [64]. Read level 
mappings analysis was accomplished using cgatools, SAMtools 
(samtools.sourceforge.net), and visualized using the Integrative Genomics Viewer (Broad 
Institute, Cambridge, MA) [65,66]. 
 
Somatic Copy Number Alteration Detection and Analysis 
Adaptation of the GISTIC algorithm for the WGS coverage data yielded few results, 
often limited to what could be observed through gross visual inspection of the data using 
R or Circos based plots (data not shown). Instead of trying to first call segments in 
individual patients, we sought to identify only the recurrent somatic alterations, for each 
of the 100kb normalized coverage window provided by Complete Genomics. Coverage in 
the tumor sample was divided by the coverage in the paired control sample for each 
matching position, resulting in coverage ratios for each window (tumor/control). After 
log2- transforming these coverage ratios, the means and standard deviations were 
determined. The CNA status (amplification/deletion) is assigned to a window if coverage 
ratio is two standard deviations away from the mean. The significance of the observed 
number of CNA at a given position across the ten tumor/control samples pairs was 
determined by randomizing the coverage position to assess the probability of observing 
the number of alterations at each position by random chance as follows: 
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𝑃! = #  𝑜𝑓  𝑡𝑖𝑚𝑒𝑠  [𝑛𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑡𝑖𝑚𝑒𝑠  𝑟𝑎𝑛𝑑𝑜𝑚𝑖𝑧𝑒𝑑  𝐶𝑁𝐴  𝑎𝑡  𝑥 > 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑  𝐶𝑁𝐴]𝑡𝑜𝑡𝑎𝑙  𝑛𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑟𝑎𝑛𝑑𝑜𝑚  𝑖𝑡𝑒𝑟𝑎𝑡𝑖𝑜𝑛𝑠  
Randomization was performed on the ten-paired samples at each iteration, using 100 
iterations to determine significance. 
 
Copy number alteration characterization analysis was conducted by distributing identical 
sets of alterations across the genome. Each alteration was checked to make sure it did not 
cross a chromosomal boundary and frequency of events on chromosome X was weighted 
by the percentage of males in the population. Resulting regions were then checked for 
overlap with RefSeq genes, which were in turn cross-listed with the Catalogue of Somatic 
Mutations in Cancer (COSMIC) census data. This processes was repeated 10,000 times 
with statistical significance determined by approximate permutation testing. 
 
Bioinformatic Analysis 
Ingenuity Pathway Analysis (Ingenuity Systems Inc, Redwood City, CA) was used for 
functional enrichment and biomarker identification. Three-dimensional structure of 
CXCR4 (molecular modeling database ID: 85802) relative to somatic variant findings 
was visualized using Cn3D (www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml) [67,68].  
Statistics and clinical data analysis were performed with R (R Foundation for Statistical 
Computing, Vienna, Austria). Unless otherwise noted, statistical significance was 
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calculated using a Wilcoxon rank sum test and the Fisher’s exact test for ordinal and 
categorical data respectively. 
 
Validation 
Selected small variants and translocations were validated using Sanger sequencing. 
Comparative PCR and Sanger Sequencing of germline and WM tumor samples was used 
to confirm the somatic status of translocations and small variants respectively. Twenty 
nanograms of genomic DNA was used for PCR amplification. Amplified fragments were 
isolated by QIAquick gel extraction kit (Qiagen, CA) prior to Sanger sequencing. A list 
of sequencing primers used for each validated variant can be found in Appendix 1. One 
patient with an MLL2 mutation had extensive WM tumor involvement in the PBMC 
compartment and the CD19 depletion was unable to remove all of the malignant cells. 
For this sample, a reduction in the tumor specific signal was used for somatic 
confirmation. Samples for the 147 patient validation cohort were prepared in an identical 
manner to the WGS cohort and screened for CXCR4 using the same primers and 
conditions. Thirty of these samples were also used for copy number validation. Copy 
number alterations were validated using paired tumor and germline samples with 
TaqMan copy number assays Hs02983032_cn, Hs02674368_cn, Hs04751460_cn, 
Hs06239749_cn, Hs03264429_cn, Hs06737553_cn, Hs06150935_cn, 
Hs00721841_cn, and Hs00243939_cn using RNase P as a copy number reference 
control. Experiments were conducted and analyzed in accordance to the manufactures 
instructions (Applied Biosystems, Carlsbad, CA). All experiments were performed in 
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triplicate. Results were deemed significant if the absolute change in tumor/germline 
relative copy number was ≥ 10% and deemed statistically significant using a two-tail t-
test (p≤0.05). 
 
Section Three – Experimental Results 
The median fully called fraction of the genome was 95.9% (range 94.7-97.1%; Figure 
4A). The analyses for single nucleotide variation (SNV) transition/transversion ratio 
corresponded with the expected median of 2.14 (range 2.13-2.15; Figure 4B). Gross 
mapping yield was comparable across all 40 samples with a median of over 184.2 giga-
bases (range 171.6-262.0 Gb; Figure 4C). 
 
 
 
 
 
 
 
 
  
  
Figure 4 Whole genome sequencing metrics.  
The 40 whole genome sequencing samples were separated by cohort: germ line peripheral blood (PB) mononuclear 
CD19-depleted cells (n=10), WM bone marrow CD19+ paired with the former (n=10), and unpaired WM bone marrow 
CD19+ (n=20). (A) Percentage of the genome for which both alleles could be called. (B) the transition/transversion 
ratio by cohort. (C) Gross mapping yield by cohort. 
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Somatic Small Variant Analysis 
WGS findings were filtered for novel non-synonymous variants as described in the 
methods section. This identified 5,835 variants in 4,427 genes. The 10-paired genomes 
were used to identify genes containing at least one somatic variant (Figure 4A). Variant 
data from all 30 WM tumor genomes were then fit to this model wherein each affected 
gene was categorized as potentially somatic, germline, or unclassified if variants were 
only observed within the 20 unpaired samples (Figure 5B).  
 
Figure 5: Mutated gene frequency in the whole genome sequencing data.  
A pie chart of the genes affected by somatic mutations demonstrating that only 10% of such genes were observed in 
more than two patients (A). A full breakdown of affected genes by somatic category and frequency is shown in (B). 
Unclassified indicates that none of the patients with the affected gene were in the 10-paired cohort. 
 
Genes were further categorized by mutational frequency and validated based on 
bioinformatic strength and biological relevance, using Sanger sequencing of both tumor 
and germline DNA. Primers and representative chromatograms are provided in Appendix 
1. A full list of somatic mutations affecting genes in the COSMIC cancer gene census are 
shown in Appendix 2 [69]. 
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The most recurrent somatic finding was a T/C mutation in MYD88 resulting in a leucine 
to proline substitution at position 265 (L265P) that was observed in 27/30 (90%) WM 
patients. This is a known activating mutation that was first recognized by Ngo et al. in 
29% of Activated B-Cell (ABC) subtype of DLBCL [70]. In addition to the L265P 
activating substitution in the primary transcript, this mutation results in a stop loss in two 
of the alternative isoforms. The functional significance for these shorter transcripts in 
MYD88L265P mutated cells remains to be clarified. A subclonal C/G mutation that was 
also recognized in the study by Ngo et al., was also found that resulted in an amino acid 
substitution (S219C) in one patient who also had the MYD88L265P mutation [70]. No 
other mutations in MYD88 were observed in this cohort. 
 
To better understand the genomic events in MYD88 wild type (WT) patients, we sought 
to identify somatic mutations that were exclusively present in the 3 MYD88WT patients. 
Cross listing these genes with COSMIC, we observed that 2 of these 3 (67%) patients had 
damaging mutations in MLL2 while mutations in the genes JAK2, PRCC, SUZ12, 
BCL10, KDM6A, and SETD2 were each observed once. Sanger sequencing confirmed 
the somatic presence of MLL2 mutations in these patients, both of whom were noted to 
have high levels of circulating B-cells and CD23+ BM WM LPC which are both 
uncommon findings in WM patients [2,71]. While a larger sample size is needed to 
determine if the high frequency of MLL2 mutations is typical of the MYD88WT WM 
population, it nonetheless represents a gene of great interest since MLL2 mutations are 
highly recurring in follicular lymphoma and DLBCL patients [72].  
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The next most common somatic mutation that was observed was in the G protein coupled 
receptor (GPCR) CXCR4. CXCR4 is a chemokine receptor that promotes WM survival, 
migration, and adhesion to the BM stroma through interactions with its ligand SDF-1α 
[73]. Eight of 30 (27%) patients harbored one of 5 somatic variants in CXCR4, each of 
which were identical or functionally similar to mutations associated with Warts, 
Hypogammaglobulinemia, Infection, and Myelokathexis (WHIM) syndrome [74,75]. 
 
Figure 6: Somatic CXCR4 mutations in WM are similar to those found in WHIM syndrome. 
Somatic CXCR4 nonsense and frame shift mutations found in 177 WM patient samples. (A) Protein sequence for the 
canonical full-length transcript (NP_003458.1) demonstrates that similar to the variants responsible for WHIM 
syndrome, these mutations result in a truncation of the cytosolic tail containing the regulatory phospho-serines leaving 
the seven transmembrane helix region involved in signaling and ligand binding intact. (B) The crystal structure of 
homodimeric CXCR4 with the carboxyl terminal tail highlighted in yellow and indicated by the white arrows. (C) 
Precise location and number of WHIM-like somatic mutations in WM at transcript level and detailed mutation type 
summary of the most frequently mutated amino acid S338. 
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WHIM syndrome is a rare, autosomal dominant genetic disorder that is caused by 
frameshift or nonsense mutations in the carboxyl-terminal (C-terminal) cytoplasmic tail 
of CXCR4. These mutations occur after the last of the seven transmembrane helices, 
destroying the C-terminal tail but leaving the regions responsible for ligand binding and 
down stream signaling via G proteins intact [68]. CXCR4 C-terminal mutations result in 
the loss of regulatory serines and impaired internalization leading to prolonged activation 
[76–78]. To validate this finding, we screened an independent cohort of 147 WM patients 
for CXCR4 mutations by Sanger sequencing. Combined with the 30 patients in the WGS 
cohort whose results were validated by Sanger sequencing, 51/177 (28.8%) patients had 
C-terminal mutations in CXCR4. Among these 177 patients, 160 demonstrated the 
MYD88L265P mutation (Figure 6). Importantly, 50/51 (98%) of the patients with CXCR4 
C-terminal mutations also carried the MYD88L265P mutation. Conversely, 16/17 (94.1%) 
of the MYD88 wild-type patients were wild-type for CXCR4 (p=0.026).  
 
Other genes with validated somatic mutations in this series included ARID1A (5/30; 
17%), CD79B (2/30; 7%), TP53 (2/30; 7%), MYBBP1A (2/30; 7%), MUC16 (1/30; 3%), 
TRAF2 (1/30; 3%), TRAF3 (1/30; 3%), RAG2 (1/30; 3%), and NOTCH2 (1/30; 3%) of 
patient samples (Figure 7). 
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Figure 7: Summary of validated small variant data.  
Validated somatic mutations by patient in the WGS cohort (A). Somatic status of all findings was confirmed by 
germline Sanger sequencing. Overall frequency of validated somatic mutations (B). 
 
Structural Variant Analysis 
Structural variants were inferred from high confidence discordant mate-pair and relative 
coverage data supplied by Complete Genomics. To gain further insight into the SV events 
underling WM, we combined individual patient data for LAF, heterozygous call rate, 
normalized relative coverage, somatic CNAs, and somatic SV calculations with cohort 
wide small variant distribution and CNA regions of statistical significance. The 
combination of these data as exemplified in Figure 8 for a single patient permits us to 
observe the relationship between heterozygous call frequency (B), LAF (D), and the 
chromosome 6q deletion present in this sample (C). Moreover, it also examines how the 
CNA found in this patient overlaps with statistically significant CNA regions in the entire 
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cohort (E). Furthermore, one can also observe how translocations link the amplifications 
on chromosomes X and 3 with the deletions on chromosomes 6 and 11 respectively (F). 
These analyses also aid in the detection of complex events such as aUPD, which can be 
observed in chromosomes 3p and 21 in Figure 8. The most common aUPD found in this 
study was at 3p that occurred in 4/30 (13%) WM patients, and whose location and size 
were highly conserved between patient samples (Figure 9). This locus included the 
MYD88L265P mutation, resulting in a homozygous MYD88L265P mutation in these 
patients.  
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Figure 8: Integrative visualization of structural variation in a WM patient genome.  
(A) Predicted novel protein damaging variants from 30 WM tumor sequences are shown in red if somatic, blue if 
germline, purple if unclassified, or green if validated. Size reflects frequency in the population. (B) Rate of 
heterozygosity averaged over a 500kb window. (C) Relative copy number is shown in black and highlighted green for 
loss and blue for amplification. Orange dots represent normalized relative coverage. Each light grey line represents a 
full copy loss/gain from expected levels assuming a diploid genome. (D) Lesser allele fraction averaged over a 500kb 
window. Green dots represent values > 2 standard deviations from the mean. (E) Heat map of regions of statistically 
significant somatic copy alteration from the 10-paired genomes where red represents gains and blue represent deletions. 
(F) Structural variants and disrupted genes. Purple lines represent translocations validated by Sanger sequencing. 
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Figure 9: Acquired uniparental disomy (aUPD) in chromosome 3p in four patients with WM. 
(A) Representative excerpts from paired tumor and germline tissue documenting an aUPD on chromosome 3 for a 
single WM patient. The red histogram below the ideogram corresponds to the heterozygous call rate. Below that, copy 
number (black line) and normalized relative coverage (orange) is shown above the lesser allele fraction (LAF) 
measurements (blue). LAF values more than 2 standard deviations from the mean are shown in green. (B) Sanger 
sequencing of MYD88L265P for this patient with a near homozygous mutant signal. (C) Heterozygous call rate, LAF, 
and relative coverage for the 4 patients with aUPDs in chromosome 3p demonstrating the near identical location of the 
aUPD for the 4 affected patients. 
 
Other aUPDs were also observed on chromosomes 1, 2, 5, 9, 17, 21, and X with many of 
these affecting the validated small variant findings as shown in Table 2. 
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Table 2: Coding changes resulting from small variant somatic mutations and overlapping structural somatic 
mutations. 
Gene N Chr Position Reference Variant Zygosity Protein Note 
ARID1A 1 1 27057944 C - hom 
Y551 
Frame Shift 
Homozygous  
by aUPD 
ARID1A 1 1 27099946 C T het R1276Stop   
ARID1A 1 1 27101665 C T het Q1650Stop   
ARID1A 1 1 27106497 C T het Q2037Stop 
Opposite  
Copy Loss 
ARID1A 1 1 27107136 - A het 
S2249 
Frame Shift 
  
NOTCH2 1 1 120478125 A C het F1209V   
CXCR4 1 2 136872467 
GAAGA 
CTCAG AC het 
S344 
Frame Shift   
CXCR4 1 2 136872481 AGAT - het 
S339 
Frame Shift 
  
CXCR4 2 2 136872485 G C het S338Stop 
WHIM associated 
rs104893626 
CXCR4 3 2 136872485 G T het S338Stop 
WHIM associated 
rs104893626 
CXCR4 1 2 136872570 - T het 
T311 
Frame Shift 
  
MAP2 1 2 210557805 G C het W304C   
MYD88 1 3 38182032 C G het S219C   
MYD88 27 3 38182640 T C het L265P 
Homozygous  
by aUPD x 4 
MED23 1 6 131915434 C T het E1013K   
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Translocations were rare, and no recurring translocations were observed in the 10-paired 
samples. Validated translocations found are shown in Table 3. 
SYNE1 1 6 152708319 C T hom R2792H 
Opposite  
Copy Loss 
TRRAP 1 7 98530988 A T het D1326V   
TRAF2 1 9 139815501 G - hom L324 
Frame Shift 
Homozygous  
by aUPD 
RAG2 1 11 36615549 A G hom L57P 
Opposite  
Copy Loss 
MLL2 1 12 49425598 A G het S4297L   
MLL2 1 12 49448412 C - het 
G101 
Frame Shift 
  
TRAF3 1 14 103371839 - T het 
L448 
Frame Shift 
Opposite  
Copy Loss 
MYBBP1A 1 17 4457136 G A het P177S   
MYBBP1A 1 17 4457323 C T het R148Q   
TP53 1 17 7577114 C T het C275Y   
TP53 1 17 7577569 A C hom C238G 
Homozygous  
by aUPD 
CD79B 1 17 62006799 A T het Y197N   
CD79B 1 17 62007129 C G het 
Exon 
Boundary 
  
MUC16 1 19 9014687 G T het A12763E   
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Table 3: Translocation validation studies.  
Genetic regions Sanger sequenced before and after the translocation break point are shown for each primer set along 
with any potentially affected gene. Bridge sequences are base pairs that did not appear to align to the consensus on 
either side of the translocation. In the PCR amplification products column, the band on the left is from WM bone 
marrow CD19+ and the right is peripheral blood CD19- DNA confirming the somatic status of the translocation.  
 
 
One patient had two distinct t(2;17) translocations disrupting both alleles of RNF213. A 
t(6;X) translocation disrupting the gene BIA3 was responsible for a chromosome 6q 
deletion that was observed in another patient (Figure 8). A third patient had a 
chromothriptic event centered on chromosome 6 that made up over half of all 
translocations that were observed in this study. This chromothriptic event contributed to 
the 6q deletions observed in this patient’s tumor cells (Figure 10). In this patient, we also 
performed PCR for t(6;7) that was predicted to disrupt BMP5 and ANKRD7, as well as 
t(6;11) that was predicted to disrupt GRIA4 and PKHD1 respectively, and validated both 
of these findings. For 2 of 5 patients with paired normal/tumor genomes and in whom 6q 
deletions were identified, translocations were responsible for these regional losses.  
 
Translocation Primers Chr Band Strand Region Sequenced Affected Genes Bridge Sequence PCR Products
TGGACAATGCACTAAGTTTTCAA 2 p16.1 - 56959157-56959321
GGACTAGCATCCTGGGTTCA 17 q25.3 + 78366166-78366354 RNF213
CCACTCTCCCACCAGAACAT 2 p16.1 + 56959052-56959176
TCTTCCTCCATTATGCTATGTGG 17 q25.3 - 78366010-78366149 RNF213
TCCTGAGGGAAATTTCATGATT 6 q12 + 69583517-69583651 BIA3
TGAACACTCAATAATCCATTGC X q23 + 113677873-113678027
CGCTTCACATGAGGAAATGA 6 p12.1 - 55729436-55729533 BMP5
TTTGCAAGCCTCATGGTAAC 7 q31.31 + 117869673-117869779 ANKRD7
TGACTTCTAAATTAGGATGGCAAG 3 q13.31 - 116691296-116691481
CTGCCCTCTTGAAACAGCAT 11 q24.1 - 122166942-122167461
AAAATGTGGATGAGTCCTAAGAGG 11 q22.3 + 105686457-105686731 GRIA4
GGAAAAATGGTTGAATCAGAAGA 6 p12.3 + 51542189-51542636 PKHD1
t(3;11) --
t(6;11) --
t(6;X) --
t(6;7) --
t(2;17) #1 TT
t(2;17) #2 GAAT
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Figure 10: Detected translocations by patient sample.  
Summary of copy number and structural variants results identified in the 10 paired WM patients who underwent WGS. 
All high confidence structural variants are colored coded by the sample in which they were detected. Genes disrupted 
by structural variants are listed in purple and potential gene fusions in red. 
 
Macro-level analysis of normalized coverage for all 30 WM samples demonstrated that 
large deletions in 6q were present in 13/30 (43%) with corresponding gains in 6p in 3/13 
(23%) cases. The next most common alteration observed was an amplification of 
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chromosome 4 which occurred in 7/30 (23%) patients confirming previous FISH and 
aCGH findings [28,30]. 
 
Somatic Copy Number Alterations 
To detect small somatic deletions and amplifications, we calculated 100Kb windows of 
the log-transformed ratio of tumor to germline relative coverage in each of the paired 
genomes. Instead of attempting a typical per patient segmentation analysis, significant 
windows were then compared across all 10 patients in order to identify statistically 
significant CNA regions. CNAs consisted mostly of isolated 100Kb blocks as can be seen 
in Band E of Figure 8. A full complete list of significant copy number windows is shown 
in Appendix 3. To better characterize these highly recurrent deletions, consecutive blocks 
of equal significance were merged together to form 194 statistically significant regions 
with a median length of 100Kb (range 100Kb-4,900Kb). Of these regions, 134 (69%) 
were found outside of chromosome 6 with a median length of 100Kb (range 100Kb-
300Kb), of which 126 of 134 (94%) were restricted to a single 100Kb region. Within 
chromosome 6, CNAs were larger with only 30/60 (50%) of the CNAs constituting single 
100Kb regions (p=7.709x10-12). As large deletions affecting multiple genes can dilute a 
functional enrichment signal, we investigated the biological relevance of non-
chromosome 6 CNAs using functional enrichment analysis on the gene set affected by 
these alterations (Figure 11A).  
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Figure 11: Characterization of somatic copy number alterations (CNA) in WM.  
(A) Functional annotation for genes affected by CNA found outside of chromosome 6. The list is ordered by statistical 
significance and filtered only for duplicate functional annotations matching more than one category. (B) Deletions of 
matching size were randomly distributed across the genome in 10,000 trials. The number of affected total RefSeq and 
COSMIC genes was calculated for each group. Results represent mean values with empirical 95% confidence intervals. 
 
CNAs targeted COSMIC census genes for 14 of 172 (8.14%) genes outside of 
chromosome 6, versus 4 of 239 (1.67%) genes within chromosome 6 respectively 
(p=0.0024). To determine the probability of generating these results as a random by-
product of genomic instability, we calculated the number of total genes affected by these 
deletions (N=411) and the number of these genes found in the COSMIC database 
(N=18). We randomly distributed matching deletion sets across the genome and 
enumerated the total number of overlapping genes and the number of those genes listed in 
the COSMIC census as shown in Figure 11B. These simulations revealed a statistically 
significant increase in targeting of COSMIC genes by CNAs outside of chromosome 6. 
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Affected genes in the COSMIC census were BTG1 (9/10; 90%), FOXP1 (7/10; 70%), 
FNBP1 (7/10; 70%), CD74 (7/10; 70%), TOP1 (6/10; 60%), MYB (5/10; 50%), CBLB 
(5/10; 50%), ETV6 (5/10; 50%), TNFAIP3 (5/10; 50%), FBXW7 (5/10; 50%), PRDM1 
(5/10; 50%), TFE3 (4/10; 40%), JAK1 (4/10; 40%), MAML2 (4/10; 40%), FAM46C 
(4/10; 40%), EBF1 (4/10; 40%), STL (4/10; 40%), and BIRC3 (4/10; 40%). Other 
affected genes of interest included PRDM2 (8/10; 80%), HIVEP2 (8/10; 80%), ARID1B 
(7/10; 70%) as well as LYN (7/10; 70%). 
 
There were no singular regions of statistical significance in 6q (Figure 12A). Some 
patients had multifocal deletions in this region suggesting multiple target genes. Neither 
of the previously suspected target genes for 6q loss, i.e. PRDM1 and TNFAIP3 were 
included in the regions of highest statistical significance [23,31]. The relative coverage 
data from all 10-paired patients is shown in Figure 12B illustrating that only 3 patients 
had highly clonal deletions in 6q. Two additional patients had subclonal deletions in 6q, 
therefore 5/10 (50%) paired patients had at least subclonal loss. Deletions in HIVEP2 
(8/10; 80%) as well as ARID1B (7/10; 70%) and BCLAF1 (7/10; 70%) constituted the 
most common deletions in chromosome 6, and were present in patients with and without 
visible 6q losses. 
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Figure 12: Somatic deletions identified on chromosome 6 by WGS in WM patients.  
(A) Frequency of statistically significant chromosome 6 deletions from the 10 paired patients highlighting genes of 
interest. The positions of the deletions are mapped against chromosome 6 cytogenetic bands. (B) Relative coverage 
across chromosome 6 for each of the 10 paired samples. Losses in 6q were not always single contiguous deletions and 
some patients had deleted segments restricted to a subclone. The frequency of deletions for genes including HIVEP2 
and ARID1B were higher than the corresponding number of large block deletions.  
 
To test the validation system and examine the accuracy of the GC normalized relative 
coverage data, we used a PCR based copy number assay to validate the established 6q22 
deletion in a subset of patients (Figure 13A).  
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Figure 13: Copy number detection by real time PCR vs. whole genome sequencing.  
(A) Validation of the known 6q deletion in two patients at HINT3 (6q22.32). Graphed values represent median and 
range PCR estimated copy number.   (B) Comparison of whole genome and PCR validation estimates of relative 
somatic copy number demonstrating similar clonal estimates. 
 
Having produced the expected results, we conducted additional validation studies for 
eight of our top targets in the same five patients using commercially available assays 
(Figure 14). While many results appeared subclonal, we observed a strong correlation 
between the PCR relative copy number and WGS coverage predictions (Figure 13B).  
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Figure 14: Validation of somatic deletions in 5 patients from the whole genome sequencing cohort.  
Five patient samples, 3 from the paired and 2 from the unpaired WGS cohorts were selected for validation studies using 
PCR copy number assays. All assays were run in at least triplicate. Results represent median values and ranges with 
black and light-grey bars representing somatic and germline values, respectively. Results were normalized to germline 
copy number as determined by PCR. Deletions deemed significant by Welch’s t-test are marked with *. 
 
For MKLN1 and HIVEP2, germline CNAs were significant, and therefore tumor to 
germline relative coverage should be interpreted accordingly (Figure 15). To establish the 
frequency of these CNAs, we validated these eight findings in an independent cohort of 
30 WM patients revealing somatic losses in PDRM2 (28/30; 93%) at 1p36.21, BTG1 
(26/30; 87%) in Chr. 12q21.33, HIVEP2 (23/30; 77%) at 6q24.2, MKLN1 (23/30; 77%) 
at 7q32, PLEKHG1 (21/30; 70%) at 6q25.1, LYN (18/30; 60%) at 8q12.1, ARID1B 
(15/30; 50%) at 6q25.1, and FOXP1 (11/30; 37%) at 3p13 (Figure 16).  
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Figure 15: Germline copy number polymorphisms with somatic deletions.  
Somatic relative copy number needs to be interpreted in context. Significant germline copy number variation was noted 
in some genes as seen here with HIVEP2. 
 
CXCR4WHIM and MYD88L265P mutation status were validated in BM samples from all 30 
patients using Sanger sequencing and AS-PCR, respectively. Fewer copy number losses 
were observed in CXCR4WHIM mutated versus CXCR4WT patients (p=0.002). The total 
number of 6q CNAs in CXCR4WHIM mutated versus CXCR4WT patients was also lower 
(p=0.007; Figure 16). This was also true for any combination of two of the three 
validated 6q genes ruling out possible biasing by a single gene (p<0.023 for all).   
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Figure 16: Copy number validation studies.  
(A) Copy number results per patient for the independent 30 patient validation cohort as determined by qPCR. Somatic 
MYD88L265P and WHIM-like CXCR4 mutations were assessed in this population and annotated here for reference. The 
eight CNA targets selected for validation were chosen based on the 10 paired patient WGS analysis and technical 
validation studies. (B) Overall frequency of validated somatic CNA for the 30 patient WGS and validation cohorts. 
 
Section Four – Conclusions 
The discovery of a highly recurring somatic mutation MYD88L265P, which is present in 
90% of WM patients, represents a seminal finding in the history of this disease. The 
finding of MYD88L265P and MYD88S219C were previously described as activating 
mutations in ABC subtype of DLBCL [70]. MYD88 is an integral part of Toll like 
receptor (TLR) system and the interleukin 1 receptor (IL1R) signaling. The TLRs are part 
of the innate immune system designed to detect pathogen associated molecular patterns 
(PAMPs) such us lipopolysaccharide (LPS; TLR4), bacterial flagellin (TLR5), and 
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unmethylated CpG DNA (TLR9) [79]. MYD88 is not a kinase but acts as an adaptor 
protein for all human TLRs other than TLR3. TLR2 and TLR4 both require an additional 
adaptor protein, TIRAP. TLR and IL1R activation induce a conformational change in 
MYD88 allowing homodimerization. The homodimerization of MYD88 recruits IRAK4 
and IRAK1 to form the myddosome that triggers signaling leading to NFκB 
phosphorylation and nuclear translocation [79,80], as shown in Illustration 4. Following 
receptor activation MYD88 homodimerization recruits IRAK4 and IRAK1 to the 
complex. Recruitment of IRAK4 leads to autophosphorylation, and the subsequent 
phosphorylation of IRAK1. Activated IRAK1 induces the ubiquitantion of TRAF6, 
which is required to recruit the TAB1/TAB2/TAK1 complex that activates TAK1. TAK1 
then phosphorylates the heterotrimeric NEMO/IKK complex, activating it, and allowing 
IKKα to phosphorylate IκBα. The phosphorylation of IκBα leads to the phosphorylation 
and release of the p50 and p65 heterodimeric subunits of NFκB and the 
polyubiquitination and proteasomal degradation of IκBα. NFκB migrates from the 
cytoplasm into the nucleus where it drives inflammatory signaling. The MYD88L265P 
mutation supports MYD88 constitutive homodimerization and downstream signaling 
[70]. 
	  	  
45 
 
Illustration 4: The MYD88 signaling cascade. 
 
The second most common somatically mutated gene was CXCR4, constituting the first 
identification of a somatic mutation in this gene in any human cancer despite its frequent 
dysregulation in many malignancies [81]. All identified mutations truncated or scrambled 
the regulatory C-terminal tail of CXCR4 leaving the rest of the gene intact. These 
somatic mutations were similar or identical to the germline mutations that underlie 
WHIM syndrome [74,75]. Loss of the regulatory C-terminal tail of CXCR4 impairs 
receptor internalization leading to constitutive signaling. The activating nature of 
CXCR4WHIM mutations suggests a role in the growth and survival of WM. The fact that 
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chromosome 6q deletions were less common in patients with CXCR4WHIM mutations may 
indicate that these deletions fulfill a similar function for CXCR4WT patients. Chapter 4 
discusses CXCR4 signaling and clinical associations in greater detail. Further work will 
be needed to clarify the role of both the frequent copy number deletions and the CXCR4 
mutations in WM. 
 
Finally, the novel Fishers based CNA detection algorithm for next generation sequencing 
identified a large number of recurrent deletions and amplifications, including subclonal 
CNAs.  The genes targeted by the CNAs are strongly associated with indolent B-cell 
lymphoma and COSMIC genes. Additional functional validation of top CNA target genes 
is warranted to clarify their role in WM biology and pathogenesis. The findings are 
further discussed in Chapter 5. 
 
 
CHAPTER THREE - MYD88L265P Detection, Function, and Clinical Significance 
Section One – Introduction 
 The discovery of a highly recurrent somatic MYD88L265P mutation in WM by 
whole genome sequencing has important clinical implications. Given its frequency of 
~90%, assays could be developed to aid in differential diagnosis of WM. As the mutant 
allele burden in a DNA sample directly corresponds to the number of WM cells relative 
to normal cells, such a test may also permit response assessment and establish the 
presence of minimal residual disease. Moreover, a sensitive L265P assay could detect the 
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presence and burden of circulating WM tumor cells allowing for peripheral blood disease 
monitoring and reducing the need for repeated bone marrow biopsies. Most of all, while 
preliminary studies of MYD88 mutation signaling had been published in DLBCL, its 
contribution to the pathology of WM remains to be defined [70]. In this chapter, the 
development and validation of an allele specific (AS) polymerase chain reaction (PCR) 
assay for MYD88L265P is demonstrated. This assay has allowed for quick and accurate 
MYD88 genotyping of large patient cohorts. In addition, IRAK1/4 and MYD88 targeted 
inhibition is used to explore the role of MYD88L265P in NFκB signaling in Waldenström’s 
Macroglobulinemia. 
 
Section Two – Materials and Methods 
Patients and Sample Collection 
Patients with WM and IgM MGUS met the consensus criteria for diagnosis as set forth at 
the Second International Workshop on WM and were untreated [2]. WM BM 
mononuclear cells were sorted using magnetic beads as directed by the manufacturer 
(Miltenyi, Auburn, CA). CD19+ selected cells from BM aspirates from MGUS patients 
were provided by Dr. Enrica Morra (Niguarda Ca’ Granda Hospital, Milan, Italy) 
CD5+CD19+ selected cells from PB of CLL patients were provided by Dr. Jennifer 
Brown (Dana-Farber Cancer Institute, Boston, MA), CD19+ selected cells from tumor-
involved BM or PB of splenic MZL patients were provided by Dr. Luca Arcaini 
(University of  Pavia, Pavia, Italy), whereas CD138+ selected cells from BM aspirates of 
MM patients (including 3 with IgM-secreting disease) were provided by Drs. Nikhil 
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Munshi and Kenneth Anderson (Dana-Farber Cancer Institute, Boston, MA). CD19+ 
selected cells from PB (n = 30) or BM (n = 10) from healthy donors were also collected 
for use in AS-PCR assays. BCWM.1 (from our laboratory) and MWCL-1 cells (kindly 
provided by Dr Stephen Ansell, Mayo Clinic, Rochester, MN) are WM cell lines that are 
heterozygous for MYD88L265P, whereas OCI-LY3 (homozygous for MYD88L265P) and 
OCI-LY19 (MYD88WT) are DLBCL cell lines kindly provided by Dr Mark Minden 
(Princess Margaret Cancer Center, Toronto, Canada) [82–84]. These cell lines were used 
in the development of the MYD88L265P AS-PCR assay. DNA was extracted using Allprep 
DNA/RNA mini kit (QIAGEN, Valencia, CA). 
 
To assess the performance of the MYD88 AS-PCR assay in PB samples, PB was 
collected from 230 WM and 12 IgM MGUS patients. The clinical characteristics of these 
patients can be seen in Table 4. Of the 230 WM patients, 132 had bone marrow aspirates. 
All IgM MGUS patients had bone marrow aspirates. CD19+ cells from bone marrow 
aspirates were isolated using CD19+ Microbead selection (Miltenyi Biotec, Auburn, CA). 
The CD19+ cells from PB were isolated using Dynabeads CD19+ pan B kit (Life 
technologies, Carlsbad, CA). Peripheral blood (8ml) and Dynabeads (200 µl) were mixed 
and incubated for 20 min at 4oC with gentle rotation. The beads were then collected by 
magnet and washed three times with isolation buffer. Three hundred fifty µl of RLTplus 
cell lysis buffer (AllPrep DNA/RNA Mini Kit, Qiagen, Valencia, CA) were added to the 
beads and DNA was extracted according to the manufacturer’s protocol (Qiagen).  
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Table 4: Patient characteristics from the paired peripheral blood and bone marrow samples 
Clinical data obtained from patient medical records following informed consent. 
 
All human samples were obtained after approval from the Dana-Farber Cancer Institute 
Institutional Review Board. Informed consent from individuals for sample use was 
obtained in accordance with the Declaration of Helsinki.  
 
AS-PCR Assay for MYD88L265P  
Two reverse primers were designed to differentiate the mutant and wild-type allele of 
MYD88L265P. To optimize the specificity, internal mismatches were introduced at the 
third and second positions from the 3′ end to the L265P and WT primers respectively. 
The mutant-specific reverse primer was 5′-CCTTGTACTTGATGGGGAaCG-3′ and the 
wild-type-specific reverse primer was 5′-GCCTTGTACTTGATGGGGAaCA-3′ with the 
lower case “a” indicating the mismatch base in both designs. The common forward 
primer was 5′-AATGTGTGCCAGGGGTACTTAG-3′. PCR was performed in a final 
volume of 25 µL with 50 nM of each primer and 50 ng DNA using PCR SuperMix High 
Fidelity (Life Technologies, Grand Island, NY). Thermal cycling conditions were: 2 
minutes at 94°C, followed by 40 cycles of 94°C for 30 seconds, 57°C for 30 seconds, and 
68°C for 30 seconds, with a final extension at 68°C for 5 minutes. The amplified PCR 
products (159 bp) were separated on 2% agarose gels. To confirm the sequence, PCR 
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products were purified by QIA quick gel extraction kit (Qiagen) and sequenced using 
both forward and reverse PCR primers.	  
 
Illustration 5: MYD88L265P allele specific primer design. 
The allele specific PCR primers amplify DNA in the 5th exon of MYD88. They share the forward 5’ primer but differ 
in the reverse. The mutant specific primer shown above compliments the reference except for the initial T/C mutant 
position and the 3rd base mismatch, a feature shared by the wild type specific primer, which helps ensure sensitivity by 
weakening the complementarity sufficiently to prevent mispriming to the off target allele. For the real time assay it is 
important that the reference primer set pick up both alleles, so while the forward primer is again the same, the reverse is 
an additional 53 bases down stream from the allele specific primer shown above. 
 
Quantitative detection of the MYD88L265P mutation was achieved using the same primers 
with Power SYBR Green PCR Master Mix according to the manufacturer’s instructions 
on the ABI Prism 7500 Sequence Detection System (Applied Biosystems, Foster City, 
CA). PCR was performed in a final volume of 25 µL with 25 nM of each primer and 50 
ng DNA. Thermal cycling conditions were: 10 minutes at 95°C, followed by 40 cycles of 
95°C for 15 seconds and 60°C for 60 seconds. Each sample was assayed in triplicate. The 
standard curve for MYD88L265P was generated by a serial dilution of the mutant DNA 
with the wild-type DNA (50%, 10%, 2%, 0.4%, 0.08%, and 0%). For the corresponding 
reference PCR, the forward primer is the same as the one used for the AS-PCR (5′-
AATGTGTGCCAGGGGTACTTAG-3′) and the reverse primer is located at 53 bp 
downstream of the AS-PCR primer (5′-TGGTGTAGTCGCAGACAGTGA-3′).  
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To confirm AS-PCR results, Sanger sequencing was used as previously reported in 
Chapter 2. The forward PCR primer 5′-GGGATATGCTGAACTAAGTTGCCAC-3′ and 
reverse PCR primer 5′-GACGTGTCTGTGAAGTTGGCATCTC-3′ were designed to 
amplify a 726-bp fragment covering the MYD88L265P site. Amplified PCR products were 
isolated by QIA quick gel extraction kit (Qiagen) and sequenced using the reverse PCR 
primer and a sequencing primer 5′-GCTGTTGTTAACCCTGGGGTTGAAG-3′. 
 
MYD88 Signaling Studies 
The WM cell lines BCWM.1 and MWCL-1 along with MYD88WT Ramos [85], MM1S 
[86], RPMI-8226 [87], and U266 [88] cell lines were incubated overnight with either 
100µM of a control peptide, 100µM of an inhibitor of MYD88 homodimerization (IMG-
2005-5, Imgenex, San Diego, CA), a dimethylsulfoxide (DMSO) vehicle control, or 
10µM of a dual interleukin-1 receptor–associated kinase (IRAK) 1 and IRAK4 kinase 
inhibitor (407601, EMD, Rockland MA) [89,90]. Western blotting was performed with 
the use of total protein and phosphospecific antibodies for nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor, alpha (IκBα) (Ser32) (Cell Signaling, 
Danvers, MA), nuclear factor κB (NF-κB) p65 (Ser529) (BD Biosciences, San Jose, CA), 
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Santa Cruz Biotechnology, 
Dallas, TX). The nuclear and cytoplasmic expression of NF-κB p65 was examined by 
means of immunofluorescence staining, using a rabbit polyclonal antihuman NF-κB p65 
antibody (Cell Signaling), followed by donkey anti-rabbit IgG-DyLight 488 secondary 
antibody (Abcam, Cambridge, MA). 
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Statistical Analysis 
Clinical correlations with MYD88L265P mutational status were assessed using an analysis 
of covariance (ANCOVA). Correlation of delta CT (dCT) and BM response was assessed 
using Spearman’s rank correlation. Categorical variables were compared with the use of 
Fisher's exact probability test, and ordinal variables with the use of the Mann–Whitney U 
test. P values were adjusted for multiple comparisons according to the method of Holm 
and Bonferroni. P values of 0.05 or less were considered to indicate statistical 
significance. Calculations were performed with the use of the R statistical package (R 
Foundation for Statistical Computing). 
 
Section Three – Experimental Results 
MYD88L265P AS-PCR in WM Bone Marrow Aspirates 
In order to obtain large quantities of MYD88L265P mutant and wild type DNA, Sanger 
sequencing was used to screen cell lines for the mutation. These studies revealed that the 
WM cells lines BCWM.1 and MWCL-1 were both heterozygous for MYD88L265P and 
confirmed that the DLBCL cell lines OCI-LY3 and OCI-LY19 were homozygous for 
MYD88L265P and MYD88WT, respectively. DNA isolated from these lines was used to test 
the sensitivity of our allele specific PCR primers with decreasing concentrations of 
mutant DNA as shown in Figure 17. The resultant PCR products were Sanger sequenced 
to confirm specificity.  
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Figure 17: Allele specific PCR products 
OCI-LY3 DNA was serially diluted with OCI-LY19 DNA. Using water as a negative control, 50ng of each resulting 
mixture were amplified with the mutant and wild type AS-PCR primers for 40 cycles and run on a 2% agarose gel with 
a molecular weight ladder (MW). 
 
No additional bands were observed and the band strength decreased in proportion to the 
decreasing mutant concentration, indicating the possible use of the primers in the 
development of a real time PCR assay. In order for the reference amplification control 
signal to be independent of L265P mutation status, an additional reference primer 59 base 
pairs downstream was designed for use in the AS-PCR real time assay. AS-PCR 
assessment of serial dilutions of L265P allele concentration demonstrated its ability to 
detect the mutation at concentrations as low as 0.08% while maintaining a 2 dCT 
difference from the 0% negative control. Therefore, the assay has the ability to detect 
MYD88L265P concentrations at least as low as 0.1%, which represents a 100-fold increase 
over the 10% to 20% sensitivity associated with Sanger sequencing. To further test the 
specificity of the system, a standard curve of the log concentration versus the CT value 
was generated in triplicate resulting in a R2 of 0.9975 as shown in Figure 18A. Standard 
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curves can be used for quantification as well as indication of specificity as the off target 
amplification will start to dominate at lower target allele concentrations resulting in a 
non-linear relationship to log concentration.  
 
Figure 18: Real time AS-PCR specificity 
As the quantity of product doubles with each cycle of PCR, there should be a linear relationship between cycle 
threshold (CT) of detection and the log concentration of the target allele (A). This standard curve can also be used for 
quantification of reactions on the same PCR plate. Dissociation curve analysis of the same data revealed one minor off 
target product with a melting point of 80°C in samples with target allele concentrations of .4% and lower (B). The 
primary on target PCR product melting point was detected at 84°C. Derivative refers to the negative derivative or -1 x 
the rate of change of florescence with respect to temperature. 
 
Dissociation curve analysis was used to detect the presence of off target amplification. As 
SYBR green is a detector of double stranded DNA, there is an abrupt drop in florescent 
intensity at the melting point of each PCR product as the temperature increases. As each 
PCR product is likely to have a different melting point, these dissociation peaks detect off 
target amplifications in real time systems much like checking for additional bands in an 
A 
B 
CT
#
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agarose gel using conventional PCR. As seen in Figure 18B, melting point dissociation 
curve analysis revealed only one additional minor peak that was present only in samples 
with a 0.4% MYD88L265P concentration or lower.  
 
The AS-PCR assay was used to evaluate 40 healthy donors, 9 IgG MGUS, 24 IgM 
MGUS, 26 CLL, 14 MM, 20 MZL, and 104 untreated WM patient samples for the 
MYD88L265P mutation. Commonly used graphing techniques such as box plots and bar 
graphs assume a central tendency in the data and can mask the presence of distinct 
subpopulations. Therefore, kernel density plots were overlaid with normal box plots, to 
form violin plots for each of the sample cohorts (Figure 19). 
 
Figure 19: MYD88L265P AS-PCR results from healthy donors (HD), patients with WM, and patients with related 
malignancies. 
Violin plots showing the delta cycle threshold (dCT) AS-PCR results for the MYD88L265P assay. Low dCT values 
indicate minimal difference with the reference assay and therefor a strong signal for the mutation. High dCT values 
indicate that more PCR cycles were necessary to detect the mutation and therefore have a lesser allele burden or are 
MYD88WT. Positive versus negative calls were determined by standard curve. The shaded region represents the area 
between the lowest positive and highest negative dCT. The samples circled in red have all since progressed to WM.  
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With observed mutation rates of 1/26 (4%), 0/14 (0%), 2/20 (10%) for CLL, MM, and 
MZL respectively versus 97/104 (93%) in WM (p<5x10-13 for all comparisons), these 
studies confirmed that MYD88L265P, while not unique, is sufficiently characteristic of 
WM disease to be useful in its differential diagnosis. Interestingly, the 2 MZL samples 
that were MYD88L265P mutated displayed characteristics that were in line with the 
diagnosis of WM versus MZL. In addition, the violin plots demonstrated the presence of 
separate positive and negative distributions within the IgM MGUS samples that would 
have been obscured with an interquartile box plot. IgM expressing MGUS has the highest 
probability to transform into a malignant entity, most commonly WM, of all of the 
MGUS subtypes [19]. The mutation for MYD88L265P, was frequently observed in this 
population (13/24; 54%), but not in IgG MGUS (0/9; 0%; p=0.005). Whether these 
results indicate that MYD88L265P is the transformation event or represents a 
subpopulation of MGUS most likely to evolve into WM remains to be clarified. 
However, three individuals with IgM MGUS with the highest MYD88L265P allele burden 
(circled in red in Figure 19) subsequently transformed to WM. 
 
To evaluate if MYD88L265P AS-PCR could be used for disease monitoring and response, 
seven MYD88L265P mutated samples were identified where both pre-treatment and post 
treatment DNA was available. Of the seven patients, four received the MTOR inhibitor 
everolimus, two received combination cyclophosphamide, dexamethasone, and rituximab 
therapy, and one received bendamustine with rituximab. The percent change in dCT for 
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MYD88L265P strongly correlated with the percent change in BM involvement as shown in 
Figure 20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Correlation between bone marrow and AS-PCR responses to therapy. 
The post therapy percent change from pre-therapy baseline in bone marrow WM LPC involvement versus MYD88L265P 
AS-PCR dCT values for the same time points demonstrate a strong correlation between the change in MYD88L265P 
allele burden and change in bone marrow disease involvement (rho= 0.929;p=0.007).  
 
These findings support further investigations of MYD88L265P AS-PCR in disease 
monitoring and response assessment. The concordance of the complete remission with 
the switch to being undetectable by AS-PCR also raises the possibility of using 
MYD88L265P as a marker of minimal residual disease, as well as the establishment of a 
molecular complete response category akin to that employed in other malignancies such 
as t(11;14) (mantle cell lymphoma), t(14;18) (follicular lymphoma) and t(9;22) (chronic 
myelogenous leukemia) [91,92]. Prospective clinical trials will be necessary to assess the 
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utility and potential clinical significance of molecular response assessment using 
MYD88L265P quantitative AS-PCR. 
 
MYD88L265P AS-PCR in WM Peripheral Blood 
 A peripheral blood assay could potentially be used for diagnostics and disease 
monitoring, reducing the need for invasive and costly BM biopsies. MYD88L265P allele 
concentrations were therefore assessed by AS-PCR in paired bone marrow and peripheral 
blood samples. This cohort included all stages of WM from the IgM MGUS precursor, to 
smoldering WM (defined as meeting WM diagnostic criteria, but not in need of therapy), 
symptomatic WM (untreated, in need of therapy), to previously treated WM (Figure 21). 
 
Figure 21: MYD88L265P AS-PCR in peripheral blood and bone marrow by disease state 
Violin plots of the dCT values from the MYD88L265P real time assay. The horizontal bar represents the area separating 
the dCT values from the highest positive and the lowest negative samples. Paired bone marrow and peripheral blood 
samples are shown for each disease state which encompassed 12 IgM MGUS, 13 smoldering WM, 48 symptomatic 
WM, and 66 previously treated WM samples.  
 
In this analysis, 6/12 (50%) of IgM MGUS, 12/13 (92%) of smoldering WM, 46/48 
(96%) of symptomatic WM, and 61/66 (92%) of the treated WM patients were positive 
for MYD88L265P by BM AS-PCR. A very strong concordance between the BM and PB in 
untreated samples was observed with 1/12 (8%) of IgM MGUS, 1/13 (8%) of smoldering, 
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and 0/48 (0%) of symptomatic WM paired samples demonstrating discordant mutation 
calls. However, the discordance rate was significantly higher in previously treated WM 
patients (16/66; 24%) when compared to either untreated or symptomatic WM patients ( 
p<0.0002). For IgM MGUS and untreated WM, there was a tight correlation between the 
BM and PB data regardless of disease state, which can be seen in Figure 22. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Correlation between peripheral blood and bone marrow dCT results in IgM MGUS and untreated 
WM patients 
A total of 12 IgM MGUS, 13 smoldering and 48 symptomatic WM patient samples were assessed for BM and PB 
MYD88L265P dCT AS-PCR levels. Spearman’s rank correlation rho was 0.835 with p = 2.2x10-16 for the combined data. 
No significant differences were noted between the disease states. 
 
Compared to our BM AS-PCR data, peripheral blood testing for MYD88L265P showed a 
sensitivity of 0.983 (95% CI 0.895-0.999) and 0.833 (95% CI 0.365-0.991) with a 
specificity of 1 (95% CI 0.310 -1.00) and 1 (95% CI .517-1.00) for untreated WM and 
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IgM MGUS respectively. More importantly, the chance that a positive finding was truly 
positive (positive predictive value) was 100%, and the chance that a negative finding was 
truly negative (negative predictive value) was 75% in untreated WM. Likewise, the 
positive predictive value for IgM MGUS was 100% with a negative predictive value of 
86%. These studies indicate that a positive result from the peripheral blood assay can be 
used with a high degree of confidence and that borderline negative results may need to be 
supplemented with follow up BM testing. 
 
The test did not perform as well in previously treated WM samples with a sensitivity of 
0.738 (95% CI 0.607-0.838) and a specificity of 1 (95% CI 0.463-1.00), resulting in the 
same 100% positive predictive value but now with a negative predictive value of only 
24%. While the lack of false positive findings leaves room for clinical utility in this 
population, the high false negative rate indicates that patients would need BM testing to 
confirm a negative result. To better understand the nature of these findings we established 
a universal dCT cutoff of <9.6 for positivity for either assay in this dataset and plotted 
BM dCT versus PB dCT in previously treated and symptomatic WM seen in Figure 23. 
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Figure 23: Elimination of circulating MYD88L265P WM LPC in the peripheral blood of previously treated WM 
patients 
Forty eight symptomatic (red) and 66 previously treated (blue) WM patient samples were assessed for MYD88L265P in 
both bone marrow and peripheral blood CD19+ cells by AS-PCR. The <9.6 dCT cut off for positivity established 
through standard curve analysis divides the graph into four quadrants based on PB and BM positivity. The previously 
treated WM samples included several patients who where strongly positive in the bone marrow and strongly negative in 
the peripheral blood indicating a lack of circulating MYD88L265P not observed in untreated WM. 
 
A number of WM cases were strongly positive in the BM, but strongly negative in the PB 
indicating a change in the underlying post therapy biology of these patients, and a lack of 
circulating WM MYD88L265P LPC rather than insufficient sensitivity. The most 
commonly used therapeutic agent in the treatment of WM, the anti-CD20 monoclonal 
antibody rituximab, is potent against circulating cells and has a long half-life of three 
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weeks in NHL which could account for the PB versus BM differences [93,94]. 
Alternatively, there is evidence that the bone marrow microenvironment provides 
additional growth and survival support for WM cells and therapy may create a selective 
pressure for cells that stay attached to the bone marrow [35,37,95–98]. Additional studies 
will be needed to better understand the significance of these findings. 
 
Clinical significance of the MYD88L265P Mutation 
To evaluate potential clinical differences in WM patients based on the presence or 
absence of the MYD88L265P mutation, a cohort of 96 untreated WM patients with 
available BM WM LPC DNA was collected. Using AS-PCR testing, 8 patient samples 
ultimately tested negative for the MYD88L265P mutation. The details for this patient 
cohort are shown in Table 5.  
 
Table 5: Median and range clinical statistics for MYD88L265P mutant versus wild type  
 
 
 
Adjusting for multiple hypothesis testing using the Holm-Bonferroni method, the 
observed differences in BM, IgA, and IgM were all significant under Wilcoxon rank sum 
univariate analysis as well as multivariate linear modeling adjusting for both age and 
gender with p < 0.03 for all comparisons. 
 
 
MYD88 Gender Age (years) BM (%) IgG (mg/dL) IgA(mg/dL) IgM (mg/dL)
L265P 52M / 36F 60 (35-91) 60 (5-95) 669 (80-3120) 49 (6-516) 2760 (191-8630)
WT 3M / 5F 67 (60-82) 13 (5-50) 973 (395-1590) 162 (78-331) 780 (134-5620)
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MYD88L265P Signaling in WM 
The MYD88L265P WM cell lines BCWM.1 and MWCL-1 were treated with the MYD88 
dimerization peptide inhibitor IMG-2005-5 or a scrambled peptide control. The peptide 
acts as a decoy binding the MYD88 TIR domain preventing homodimerization and down 
stream signaling [90]. Both the inhibitor and control peptides contain an additional 
peptide sequence that allows them to pass through the plasma membrane. In addition to 
the WM cells lines, the MYD88WT lines, Ramos (Burkitt’s lymphoma), and multiple 
myeloma cell lines MM1S, RPMI-8226, and U266 were also evaluated. All cell lines 
were checked for phosphorylated and total IκBα and p65, both markers of NFκB 
activation as described in Chapter 2 (Figure 24). 
Figure 24: Suppression of NFκB signaling following MYD88 inhibition in WM, Burkitt’s lymphoma and 
multiple myeloma cell lines.  
Cell lines were incubated overnight with 100µM of peptide to allow for full cellular permeation and inhibition.  
These studies not only confirm that NFκB is highly active in WM, but also that inhibition 
of MYD88 signaling blocks NFκB activation. In contrast, the MYD88WT cell line Ramos 
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showed a strong IκBαpS32 signal at baseline, but was unaffected by MYD88 inhibition. To 
further confirm these findings, we used a chemical inhibitor of IRAK4 and IRAK1, 
EMD-	  407601 [89] (Figure 25). 
 
Figure 25: Suppression of NFκB signaling following IRAK1/4 inhibition in WM, Burkitt’s lymphoma and 
multiple myeloma cell lines.  
Cell lines were incubated overnight with 10µM of either the dual IRAK1/4 kinase inhibitor or DMSO vehicle control to 
allow for full signal inhibition. 
 
The virtual recapitulation of the MYD88 inhibitor results with EMD-407601 supports the 
conclusion that MYD88L265P is driving NFκB signaling through IRAK4 and IRAK1 in 
WM. However, full activation of NFκB requires not only phosphorylation, but nuclear 
translocation as well. To study the role of MYD88 signaling on the nuclear localization 
of NFκB, we repeated the previous experiments with both the IRAK1/4 and MYD88 
inhibitors using confocal microscopy (Figure 26). 
DM
SO
%
IR
AK
1/
4%
Inh
ibi
to
r%
DM
SO
%
IR
AK
1/
4%
Inh
ibi
to
r%
DM
SO
%
IR
AK
1/
4%
Inh
ibi
to
r%
DM
SO
%
IR
AK
1/
4%
Inh
ibi
to
r%
IκBαpS32 
IκBαTotal 
NFκB-p65S529 
NFκB-p65Total 
GAPDH 
DM
SO
%
IR
AK
1/
4%
Inh
ibi
to
r%
DM
SO
%
IR
AK
1/
4%
Inh
ibi
to
r%
BCWM.1 MWCL-1 Ramos RPMI-8266 MM.1S U266 
	  	  
65 
 
Figure 26: Localization of NFκB in WM and MYD88WT cell lines following IRAK1/4 or MYD88 inhibition.  
Merged data of DAPI nuclear staining (blue), plasma membrane F-actin (red), and NFκB-P65 (green) is shown for each 
condition.  
 
Nuclear localization was observed in both the DMSO and control peptide cases for both 
WM cell lines. This nuclear localization was markedly reduced by the introduction of 
either the MYD88 or the IRAK1/4 inhibitor, confirming that MYD88 signaling through 
the IRAK pathway contributes to NFκB in WM. 
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Section Four – Conclusions 
This chapter describes the development and application of an allele specific MYD88L265P 
assay in BM and PB samples taken from patients with WM and other B-cell 
malignancies. These studies demonstrated that not only is MYD88L265P present in 93% of 
WM patients, but it can be used to help distinguish WM from CLL, MZL and IgM MM. 
The fact that MYD88L265P was detected in 50% of IgM MGUS supports its role as an 
early oncogenic mutation for WM pathogenesis. To determine if these MYD88L265P 
MGUS patients have a higher rate of transformation to WM, larger prospective studies 
will be needed. If MYD88L265P occurs this early in MGUS/WM pathogenesis, what 
additional cellular changes are necessary for full progression to WM remains unclear. 
Given the indolent nature of the disease, it is also possible that MYD88L265P is a 
transformational event and the evolution to symptomatic disease occurs over several to 
many years. 
 
With additional validation, allele specific assays may also be used for disease response 
assessment and to confirmation of complete responses. These studies demonstrated that 
patients with MYD88L265P have statistically more significant bone marrow involvement, 
higher serum IgM levels, and lower serum IgA levels. The use of MYD88 and IRAK 
inhibitors demonstrated that MYD88L265P is driving NFκB signaling in WM, at least in 
part through the IRAK pathway. Dr. Guang Yang in our group has shown that 
phosphorylated Bruton’s tyrosine kinase (BTK), a TEC family kinase known to act 
downstream of TLR4 following LPS stimulation, is constitutively activated in the 
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presence of MYD88L265P [99]. Moreover, phosphorylated BTK associates with 
MYD88L265P in pull down experiments and contributes to NFκB signaling in WM 
independent of IRAK4 and IRAK1. He further demonstrated that inhibition of MYD88, 
IRAK1/4, or BTK could induce apoptosis in WM cells lines and primary patient cells. 
This is of critical importance as it validates MYD88L265P as a legitimate therapeutic target 
in WM. There are novel kinase inhibitors in development for the IRAK pathway and a 
BTK inhibitor, Ibrutinib, recently won FDA approval for CLL and mantle cell lyphoma. 
A clinical trial of Ibrutinib in WM was recently completed with favorable response rates 
in patients with previously treated WM. The impact of MYD88L265P and CXCR4WHIM 
mutations on Ibrutinib response is discussed in Chapter 4.  
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CHAPTER FOUR - CXCR4 Function and Clinical Significance in WM 
Section One – Introduction 
CXCR4 is a G protein coupled receptor (GPCR) that induces cell survival and migration 
towards its ligand SDF-1α (CXCL12 at the gene level). This chemokine receptor consists 
of seven transmembrane helices, the loops of which form the extracellular ligand binding 
pocket for SDF-1α and the intracellular signaling region which interacts with the 
heterotrimeric G proteins (Illustration 6). The intracellular carboxyl terminal tail (C-
terminal) of CXCR4 does not participate in G protein signaling or ligand binding but 
plays an important regulatory role [77]. Upon SDF-1α binding, CXCR4 activates Gαi by 
catalyzing the exchange of its guanine-diphosphate (GDP) for guanine triphosphate 
(GTP), releasing the heterotrimer from the receptor and dissociating the GβGγ 
heterodimer from Gαi [81,100]. The GβGγ subunits signal through the phospholipase C  
(PLC)  
 
Illustration 6: The CXCR4 signaling cascade. 
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and phosphoinsitide 3-kinase (PI3K) pathways until inhibited by another GDP bound Gαi. 
The Gαi subunit remains active, inhibiting adenylate cyclase and signaling through PI3K 
until the GTP is hydrolyzed to GDP by a regulator of G protein signaling family member 
(RGS). This G protein based signaling will continue until the C-terminal tail of CXCR4 
is activated and the receptor internalized. Upon ligand bindings, several kinases including 
G protein receptor kinase (GRK), and protein kinase C (PKC) family members 
phosphorylate serines in the C-terminal tail which recruit β-arrestins which transport the 
receptor to clathrin coated pits for internalization where the receptor can be either reset or 
degraded. During this process β-arrestins signal through the mitogen activated protein 
kinase pathway (MAPK) [78].  
 
There are several diseases associated with this pathway including bordetella pertussis, 
which causes whooping cough. Pertussis toxin (PTX) is released by the bacteria and 
specifically targets the Gαi subunit [101]. The Gαi or inhibitor Gα subunit used by CXCR4 
is so called as most Gα subunits promote the production of cyclic adenosine 
monophosphate (cAMP) through the activation of adenylate cyclase whereas Gαi inhibits 
adenylate cyclase. By preventing the GDP to GTP exchange, PTX silences Gαi signaling 
reducing the local inflammatory response to the bacteria and generating a buildup of 
cAMP. As discussed in Chapter 2, removal of serines by nonsense or frameshift 
mutations in the C-terminal tail as seen in WHIM syndrome impairs receptor 
internalization significantly extending the signal duration [74,75,102]. CXCR4 also acts 
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as a coreceptor for the human immunodeficiency virus and is up regulated in a number of 
human cancers where it is thought to play a role in tumor metastasis [76,81,103].  
 
Chapter two revealed that WHIM syndrome-like somatic mutations in CXCR4 are 
present in 29% of WM patients.  This represents the first report of somatic mutations in 
CXCR4 in any human cancer. This chapter investigates whether these mutations do 
indeed confer a WHIM-like activation of CXCR4 and resistance to WM therapy, and 
seeks to define the clinical characteristics in of this genotype in WM.  
 
Section Two – Materials and Methods 
CXCR4 Signaling 
CXCR4WT and CXCR4S338X cDNAs were subcloned into plenti-IRES-GFP vector, and 
transduced using an optimized lentiviral based strategy into the BCWM.1 and MWCL-1 
WM cell lines developed previously [104]. Five days after transduction, GFP positive 
cells were sorted and used for functional studies. Surface expression of CXCR4 was 
determined by flow cytometric analysis using a PE-conjugated anti-CXCR4 monoclonal 
antibody (BD Biosciences, San Jose, CA). To study receptor internalization, transduced 
cell lines were stimulated with or without SDF-1α (10-100 nM), and cell surface 
expression of CXCR4 determined by flow cytometric analysis and normalized to their 
respective unstimulated baseline levels.  For phosphoflow experiments, cells were fixed 
with BD Phosflow Fix Buffer1 at the indicated time point at 37oC for 10 minutes 
followed by two washes with 1X perm/wash buffer I. FACS analysis was performed 
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using conjugated antibodies to ERK1/2 pT202/pY204,  phospho-AKTpS473, and BTKpY223 (BD 
Biosciences). Results were confirmed by immunoblotting. Cell signaling studies related 
to CXCR4 signaling were performed in the presence or absence of SDF-1α (20 nM), 
ibrutinib (0.5 uM), the CXCR4 inhibitor AMD3100 (30 uM), and pertussis toxin (500 
ng). For survival studies, WM cells were incubated for 6 hours and apoptosis assessed by 
immunoblotting using antibodies for cleaved PARP and cleaved caspase 3 (Abcam, 
Cambridge MA). 
 
Ibrutinib Clinical Trial Data 
This corollary study was made possible thanks to the generous collaboration and support 
of Drs. Steven Treon (Dana-Farber Cancer Institute), Ranjana Advani (Standford 
University) and Lia Palomba (Memorial Sloan Kettering). The full clinical trial results 
are beyond the scope of this thesis but were recently reported at the 8th International 
Workshop on Waldenström’s Macroglobulinemia (www.wmworkshop.org). Briefly, 
patients received 420 mg of ibrutinib orally every day for 26 day cycles until progression 
or intolerance. All patients provided written informed consent after Institutional Review 
Board study approval. The study was registered at clinicaltrials.gov (NCT01614821). De-
identified patient trial data and matching DNA from WM BM biopsies were provided for 
correlative analysis. Sanger sequencing was employed for CXCR4 genotyping and 
MYD88L265P status was determined by AS-PCR as described in Chapter 3. 
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Clinical Characteristics CXCR4WHIM Mutations in WM 
BM aspirates and peripheral blood samples were collected after informed written consent 
from 174 untreated patients with the clinicopathological diagnosis of WM as defined by 
the Second International Workshop on WM [2]. Consensus criteria were used to 
categorize patients as having symptomatic vs. smoldering disease [105]. The Dana Farber 
Cancer Institute/Harvard Cancer Center Institutional Review Board approved the study 
that was conducted in accordance with the Declaration of Helsinki. MYD88L265P status 
was determined using the AS-PCR assay described in Chapter 3, and Sanger sequencing 
of the C-terminal domain of CXCR4 was performed using sorted CD19+ LPC from BM 
aspirates as previously reported in Chapter 2. The somatic nature of these mutations was 
determined by sequencing DNA from CD19-depleted peripheral blood cells. 
 
Statistical Analysis 
Data sets were subjected to analysis of variance and Tukey’s honest significant difference 
test was used for subsequent pairwise analysis. Ordinal data for which analysis of 
variance was not appropriate were analyzed using pairwise Wilcoxon rank sum test with 
Holm-Bonferroni correction. Nonparametric comparisons were made using the Fisher’s 
exact probability test. A p-value ≤ .05 was deemed to be significant. A multivariate 
analysis to estimate risk of death was performed using the Cox proportional hazard 
regression model. The Fleming-Harrington test was used to assess differences in Kaplan-
Meier survival curves. Calculations were performed with R (R Foundation for Statistical 
Computing, Vienna, Austria). 
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Section Three – Experimental Results 
WHIM-like CXCR4 Signaling in WM 
Sanger sequencing determined the CXCR4WT mutational status for both WM cell lines, 
BCWM.1 and MWCL-1. In order to have a model system for in vitro study, we cloned 
full length CXCR4WT and the most common WHIM-like mutation, CXCR4S338X, into our 
lentiviral vector. Each cell line was transduced with either the empty vector, CXCR4WT 
or CXCR4S338X for a total of 6 transduced lines. After the GFP+ selection to select for 
transduced cells we needed to determine that the protein was being produced.  Cells were 
stained for cell surface CXCR4 and analyzed by flow cytometry compared to an isotype 
background control as seen in Figure 27.	   
 
 
 
 
 
 
 
  
Figure 27: CXCR4 cell surface expression post transduction. 
Geometric mean fluorescent intensity (MFI) for cell surface CXCR4 (solid line) and isotype control (dotted line) for 
each of the transduced cell lines confirming an increase in CXCR4 surface protein in both the CXCR4WT and 
CXCR4S338X lines. Whereas the MWCL-1 empty vector line appears to lack CXCR4 expression, there is some 
endogenous CXCR4 observed in BCWM.1. 
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The source of the WHIM syndrome phenotype is thought to come largely from impaired 
internalization of CXCR4 [75,102]. To test this in our model system, both CXCR4WT and 
CXCR4S338X were cultured with 10nM or 100nM of SDF-1α for 30 minutes at room 
temperature and CXCR4 surface expression was compared to the their respective 
unstimulated baselines as shown in Figure 28. 
 
Figure 28: CXCR4 internalization following SDF-1α stimulation in WM cell lines.  
Surface expression of CXCR4 was determined by flow cytometry. Cells were stimulated for 30 minutes with SDF-1α 
at room temperature compared with their respective unstimulated baseline expression levels to determine the percent 
change in surface expression. Median and range values are shown. All experiments were conducted a minimum of 3 
times. P < 0.001 for all WT versus S338X comparisons. 
 
There was significant impairment of SDF-1α induced internalization in all CXCR4S338X 
cell lines. Although there was more internalization in BCWM.1 CXCR4S338X, this is 
probably linked to the higher levels of endogenous expression of CXCR4 in BCWM.1. 
Flow cytometry optimized AKT and ERK1/2 phospho-specific conjugated antibodies 
were used to test if CXCR4S338X led to stronger and/or extended downstream signaling 
over time following SDF-1α stimulation (Figure 29). The CXCR4S338X WHIM-like cell 
line demonstrated a greater induction of activated AKT and ERK1/2 that was also 
sustained longer than that of the CXCR4WT comparator. 
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Figure 29: Percent change in activated ERK and AKT over time following SDF-1α stimulation in transduced 
BCWM.1 cell lines.   
The BCWM.1 CXCR4 empty vector, WT, and S338X transduced cells were stimulated with 20nM of SDF-1α and 
evaluated for phospho AKT and phospho ERK1/2 at successive time intervals using flow cytometry. Percent change 
from baseline was normalized to the empty vector cell line at each time point to control for inter-experimental 
variation. P < 0.05 for all 2min, 15min, and 30min time points using repeated measures ANOVA of either the raw MFI 
or normalized data. Experiments were repeated a minimum of 3 times represented here as median values and range  
 
To confirm these findings and evaluate the relative contributions of G protein and β-
arrestin signaling, BCWM.1 lines were stimulated for 2 minutes with SDF-1α with or 
without pretreatment with the CXCR4 inhibitor AMD3100 or the Gαi inhibitor, PTX 
(Figure 30). The use of the CXCR4 antagonist AMD3100 demonstrated the extent of 
SDF-1α triggered CXCR4 signaling, while pretreatment with PTX indicated the extent of 
signaling mediated through heterotrimeric G proteins in this model system.  
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Figure 30: AKT and ERK1/2 signaling in BCWM.1 transduced lines by western blot.  
BCWM.1 transduced lines were pretreated with 30uM of AMD3100, 500ng of PTX, or nothing for two hours and then 
stimulated with 20nM of SDF-1α. Cell lysates were then blotted for either phospho-specific or total AKT and ERK. 
 
These studies confirmed that the induction of both pAKT and pERK is more robust in the 
CXCR4S338X engineered WM cells, and signaling is mediated through CXCR4. To 
confirm these in vitro findings, we assessed pAKT levels in WM patient BM LPC by 
immunohistochemistry before and after the initiation of therapy with the BTK inhibitor 
ibrutinib. As can be seen in Figure 31, both baseline and post ibrutinib bone marrow 
biopsies demonstrated persistently elevated levels of pAKT in CXCR4WHIM versus 
CXCR4WT WM patients. 
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Figure 31: Immunohistochemistry confirms high levels of pAKT in CXCR4WHIM versus CXCR4WT in WM 
patient bone marrow.  
Bone marrow specimens from 3 patients with CXCR4WHIM (A, B, C) and 3 patients with CXCR4WT (D, E, F) were 
stained for pAKT at baseline, and following 6 months of continuous ibrutinib (IB) therapy. Sanger sequencing revealed 
nonsense mutations for patient A (CXCR4R334X) and B (CXCR4S338X), and a frameshift (FS) mutation resulting in 
insertion of T at position 1013 for patient C (CXCR4S338FS).  
 
WHIM-like CXCR4 Mutations and Therapeutic Resistance in WM 
Given that both CXCR4 and MYD88 can activate BTK, we sought to assess the impact 
of the BTK inhibitor ibrutinib on CXCR4 signaling in WM [99,106,107] as shown in 
Figure 32. 
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Figure 32: Impact of ibrutinib on CXCR4WT and CXCR4WHIM transduced BCWM.1. 
BCWM.1 transduced cells were pretreated with either 0.5uM of ibrutinib or 30uM of AMD3100 prior to a two minute 
stimulation with 20nM of SDF-1α. 
 
The expected induction of BTK was not observed in this study, though this may be due to 
the constitutive activation by MYD88L265P. While ibrutinib effectively silenced BTK in 
all instances, it had minimal affect on SDF-1α induced pAKT or pERK1/2 in the 
CXCR4S338X cell line. Given the role of CXCR4, ERK and AKT in WM cell survival, 
SDF-1α stimulation of the transduced cell lines was employed to investigate the role of 
CXCR4S338X in protecting cells from ibrutinib-induced apoptosis [73,96,108] as shown in 
Figure 33. 
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Figure 33: SDF-1α rescues ibrutinib induced caspase 3 and PARP activation in CXCR4WHIM but not CXCR4WT 
BCWM.1 and MWCL-1 transduced lines.  
Cells were treated with 0.5uM of ibrutinib in the presence or absence of 20nM of SDF-1α and 30uM of AMD3100 for 
six hours. Cell lysates were then blotted for cleaved PARP or caspase 3, both indicative of pro-apoptotic signaling. 
 
These studies indicated that SDF-1α could mitigate PARP and caspase 3 cleavage only in 
the WHIM-like CXCR4S338X cells. To evaluate this effect in vivo, DNA and/or genotype 
data was collected from 62 WM patients who participated in a clinical trial using 
ibrutinib monotherapy in relapsed or refractory WM. Patients were genotyped for 
MYD88L265P using the AS-PCR assay previously described and for CXCR4WHIM 
mutations by Sanger sequencing. All patients with CXCR4WHIM mutations were found to 
have the MYD88L265P somatic mutation as well.   The clinical characteristics of the 
genotyped patients can be seen in Table 6.  
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Table 6: Clinical characteristics of genotyped patients receiving ibrutinib monotherapy 
 
 
 
 
Lymphocytosis has been noted in CLL patients treated with ibrutinib [109]. Since WM 
cells are thought to be more sensitive to apoptosis outside of the supportive bone marrow 
microenvironment, maximum percent change in peripheral blood absolute lymphocyte 
count was stratified by major response status [37,73,95,97] as seen in Figure 34. Given 
that CXCR4 induces cells to home to the bone marrow, the same lymphocytosis data was 
reanalyzed based on MYD88 and CXCR4 genotype status as shown in Figure 35. No 
significant differences in baseline absolute lymphocyte count were observed either by 
genotype or major response category.  
 
 
 
 
 
 
 
 
 
 
 
 
 median(range)
Gender 48M/14F
Age(Years) 63 (44-86)
Prior Therapies 2 (1-9)
BM Involvment(%) 60 (3-95)
Serum IgM(mg/dL) 3,620 (735-8,390)
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Figure 34: Lymphocytosis following ibrutinib therapy by major response category.  
The highest peripheral blood lymphocyte count observed on study was divided by the base line and stratified based on 
stable disease (SD) or minor response (MR; combined n=19) versus partial response (PR) and very good partial 
response (VGPR; combined n=43) P = 0.002. 
 
The best serum IgM response relative to baseline levels achieved on study was stratified 
by genotype confirming that CXCR4WHIM mutation status both inhibits ibrutinib induced 
lymphocytosis and is associated with inferior IgM reduction (Figure 36). Of note, patients 
with the MYD88WTCXCR4WT genotype also exhibited a poor response suggesting that 
the driver mutations present in MYD88WT WM are not dependent on the BTK pathway. 
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Figure 35: Ibrutinib induced lymphocytosis by genotype.  
The highest peripheral blood lymphocyte count observed on study was divided by the base line and stratified based on 
MYD88L265PCXCR4WT (n= 34) MYD88L265PCXCR4WHIM (n=21) and MYD88WTCXCR4WT (n=7) genotypes. P = 0.002 
for MYD88L265PCXCR4WT versus MYD88L265PCXCR4WHIM. 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: IgM best response by genotype with ibrutinib monotherapy.  
The lowest level of serum IgM achieved on study relative to baseline. IgM base response criteria are shown for 
reference. MYD88L265PCXCR4WT (n= 34) MYD88L265PCXCR4WHIM (n=21) and MYD88WTCXCR4WT (n=7) genotypes. 
P = 0.002 for MYD88L265PCXCR4WT versus MYD88L265PCXCR4WHIM. 
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To examine the role of CXCR4WHIM mediated resistance to WM therapy, we treated the 
BCWM.1 and MWCL-1 transduced lines to a variety of anti-neoplastic agents including 
the alkylator bendamustine, the nucleoside analog fludarabine, the proteasome inhibitor 
bortezomib, and the PI3K inhibitor idelalisib (Figure 37). All of these agents are active in 
WM patients [4,110]. 
 
Figure 37: SDF-1α inhibits PARP and caspase 3 cleavage in CXCR4S338X transduced cell lines 
CXCR4S338X transduced cells were treated for 6 hours with bendamustine (BENDA), fludarabine (FLUDARA), 
bortezomib (BORT), or idelalisib (IDELA) at their EC50 doses in the presence or absence 20 nM of SDF-1α  and/or 
30uM of AMD3100. 
 
Although the degree of rescue from caspase 3 and PARP cleavage varied by treatment 
and WM cell line, the rescue was blocked with the addition of the CXCR4 inhibitor 
AMD3100 confirming that this is a CXCR4 mediated effect. Prospective clinical trials 
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evaluating therapeutic response by genotype are necessary to confirm the relevance of 
these findings for predicting WM patient response.  
 
Clinical Significance of WHIM-like CXCR4 Mutations in WM 
To determine what if any clinical characteristics are associated with CXCR4WHIM and 
MYD88L265P combined genotypes, 174 untreated WM patients were evaluated for 
MYD88L265P using AS-PCR and CXCRWHIM using Sanger sequencing as shown in Table 
7.  
Table 7: Clinical characteristics of untreated WM patients by genotype. 
P-values calculated using analysis of variance. Categorical variable p-values were calculated using the Fisher’s exact 
test. P-values > 0.05 are represented by “-“. Genotypes included on this study were largely, but not exclusively 
heterozygous. 
 
 
 
While many of the findings reflect the differences between MYD88L265P versus 
MYD88WT patients described in Chapter 3, a significantly lower rate of adenopathy was 
! MYD88WTCXCR4WT MYD88L265PCXCR4WT MYD88L265PCXCR4WHIM P
n 15 109 50
Gender (M/F)  7/8 73/36 31/19 –
Age (years) 66 (42-82) 59 (40-88) 60 (34-88) 0.02
BM involvement (%) 15 (5-65) 40 (5-95) 50 (5-95) 0.02
Abs neutrophil (k/μL) 2.93 (0.72-3.7) 3.5 (1.04-8.94) 3.2 (1.52-8.2) –
Abs lymphocyte (k/μL) 1.61 (0.8-17.3) 1.73 (0.48-11.1) 1.69 (0.51-3.98) 0.03
Hemoglobin (g/dL) 11.3 (8-14.4) 11.5 (6-15.5) 11.6 (4.8-15.6) –
Platelet (k/μL) 218 (105-378) 274 (75-512) 251 (42-441) 0.01
Serum IgA (mg/dL) 140 (27-324) 61 (0-1240) 45 (7-864) –
Serum IgG (mg/dL) 734 (441-1480) 686 (138-2920) 595 (168-1330) –
Serum IgM (mg/dL) 2720 (134-5810) 3190 (345-8720) 3490 (416-8767) –
B2M (mg/L) 3.1 (2-5.5) 3.1 (1.4-10.4) 2.3 (1-9.2) –
Adenopathy 6 (40%) 59 (54.1%) 15 (30%) 0.01
Splenomegaly 6 (40%) 18 (16.5%) 8 (16%) –
Family history 4 (26.7%) 31(28.4%) 20 (40%) –
Prior MGUS history 4 (26.7%) 18 (16.5%) 8 (16%) –
Symptomatic disease 9 (60%) 69 (63.3%) 34 (66.6%) –
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associated with CXCR4WHIM mutation genotype which is consistent with the established 
role of CXCR4 directed homing to the BM.  
 
The CXCR4WHIM population can be broken up into two broad genomic categories. 
Nonsense mutations create an early termination of the protein while frameshift mutations 
add effectively random amino acids until a stop codon is encountered. These junk amino 
acids can interfere with either G protein or β-arrestin signaling. Clinical characteristics of 
the CXCR4WHIM mutations were therefore further classified based on their nonsense (NS) 
or frameshift (FS) mutation type as can be seen in Table 8. 
 
Table 8: Clinical characteristics if WM patients based on MYD88L265P and frameshift versus nonsense 
CXCR4WHIM status. 
P-values calculated using analysis of variance. Categorical variable p-values were calculated using the Fisher’s exact 
test. P-values > 0.05 are represented by “-“. Genotypes included on this study were largely, but not exclusively 
heterozygous. 
 
 
 
 MYD88WTCXCR4WT MYD88L265PCXCR4WT MYD88L265PCXCR4WHIM/FS MYD88L265PCXCR4WHIM/NS P
n 15 109 24 26
Gender (M/F)  7/8 73/36 14/10 17/9 –
Age (years) 66 (42-82) 59 (40-88) 62 (34-88) 59 (41-75) 0.05
BM involvement (%) 15 (5-65) 40 (5-95) 37 (5-90) 50 (15-95) <.01
Abs neutrophil (k/µL) 2.93 (0.72-3.7) 3.5 (1.04-8.94) 3.54 (1.52-8.2) 3.1 (1.56-6.14) 0.01
Abs lymphocyte (k/µL) 1.61 (0.8-17.3) 1.73 (0.48-11.1) 1.77 (0.96-3.55) 1.63 (0.51-3.88) –
Hemoglobin (g/dL) 11.3 (8-14.4) 11.5 (6-15.5) 11.8 (4.8-15.6) 11.5 (6.2-14.2) –
Platelet (k/µL) 218 (105-378) 274 (75-512) 275 (101-441) 208 (42-314) <.01
Serum IgA (mg/dL) 140 (27-324) 61 (0-1240) 45 (20-202) 45 (7-864) –
Serum IgG (mg/dL) 734 (441-1480) 686 (138-2920) 612 (267-978) 569 (168-1330) –
Serum IgM (mg/dL) 2720 (134-5810) 3190 (345-8720) 2895 (416-8320) 5200 (804-8767) <.01
B2M (mg/L) 3.1 (2-5.5) 3.1 (1.4-10.4) 2.45 (1.4-9.2) 2.4 (1-5) –
Adenopathy 6 (40%) 59 (54.1%) 7 (29.2%) 8 (30.1%) 0.04
Splenomegaly 6 (40%) 18 (16.5%) 2 (8.3%) 6 (23.1%) –
Family history 4 (26.7%) 31(28.4%) 9 (37.5%) 11 (42.3%) –
Prior MGUS history 4 (26.6%) 18 (16.5%) 5 (20.8%) 3 (11.5%) –
Symptomatic disease 9 (60%) 69 (63.3%) 11 (45.8%) 22 (84.6%) 0.03
Hyperviscosity syndrome 0 (0%) 10 (9.2%) 2 (8.3%) 8 (30.7%) 0.01
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This data demonstrated significant increases in BM WM LPC infiltration, serum IgM 
levels, and rates of symptomatic disease and hyperviscosity syndrome in patients with 
MYD88L265PCXCR4WHIM-NS versus MYD88L265PCXCR4WHIM-FS and 
MYD88L265PCXCR4WT genotypes. Serum IgM and BM involvement in untreated patients 
with CXCR4 FS mutations appear quite similar to MYD88L265PCXCR4WT as shown in 
Figure 38. However, patients with this genotype retained the low rate of adenopathy 
associated with the overall CXCR4WHIM phenotype and were associated with ibrutinib 
resistance in the clinical trial suggesting that FS mutations participate in WHIM-like 
CXCR4 signaling. These findings indicate that important signaling differences exist 
between the CXCR4WHIM-NS and CXCR4WHIM-FS.  
Figure 38: Differences in serum IgM and bone marrow involvement in untreated WM patients by CXCR4 
frameshift and nonsense genotypes.  
Boxplots indicating median, interquartile and range values by CXCR4 and MYD88 genotype. Symbols demarcate 
individual patient values. MYD88WT CXCR4WT n = 15, MYD88L265PCXCR4WT n = 109, MYD88L265PCXCR4WHIM/FS n 
= 24, and MYD88L265P CXCR4WHIM/NS n = 26. P=0.05, 0.01, and 0.01 for serum IgM in CXCR4WHIM-NS versus 
CXCR4WHIM-FS MYD888L265PCXCR4WT, and MYD88WT respectively. P=0.05 and 0.005 for WM BM involvement in 
CXCRWHIM-NS versus CXCR4WHIM-FS and MYD88WT respectively. Most, but not all mutations in CXCR4 and MYD88 
were heterozygous. 
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As the genotyping was largely from tissue bank samples, a great deal of follow up was 
available for many participants allowing for the study patient outcomes by genotype. An 
analysis of therapy received during follow-up revealed no significant differences in 
number or type of therapy. There were no significant differences in overall survival 
between the CXCR4WHIM-FS and the CXCR4WHIM-NS groups despite the more aggressive 
phenotype associated with the CXCR4 nonsense mutation group. However, the 
MYD88WTCXCR4WT patients demonstrated considerably poorer overall survival versus 
MYD88L265PCXCR4WT and MYD88L265PCXCR4WHIM patients as shown in Figure 39.  
 
Figure 39: Overall survival of WM patients by genotype.  
Log-rank analysis of overall survival revealed statistically significant differences based on MYD88 and CXCR4 
mutation status. The analysis was equally significant when stratified solely on MYD88L265P (p<0.0001 for both). The 
mutations in MYD88 and CXCR4 were primarily heterozygous in this study. 
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Section Four – Conclusions 
Studies using the CXCR4 transduced WM cell lines described in this chapter confirmed 
that somatic WHIM mutations exhibit the same impaired internalization and extended 
pAKT and pERK1/2 signaling observed in WHIM syndrome. SDF-1α induced longer 
and more robust activation of ERK and AKT in CXCR4S338X cell lines and constitutive 
activation of AKT was observed by immunohistochemistry in BM samples from patients 
with CXCR4WHIM mutations, which persisted despite ibrutinib therapy in these studies. 
WM. In vitro studies also suggested that resistance may extend to other therapeutic 
agents used in the treatment of WM. Those patients with FS versus NS mutations in 
CXCR4 exhibited different clinical characteristics as well, with CXCR4 NS patients 
exhibiting higher serum IgM levels, greater BM WM LPC burden, as well as increased 
incidence of hyperviscostiy and symptomatic disease. Despite the more aggressive 
phenotype associated with the CXR4 nonsense tumor genotype, there were no differences 
in overall survival by CXCR4 mutation status. Surprisingly, patients with 
MYD88WTCXCR4WT demonstrated significantly worse overall survival. The genomic 
events underlying this patient population remain to be clarified but may include 
mutations in MLL2. 
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CHAPTER FIVE – Discussion  
Section One –Whole Genome Sequencing Results 
The most pronounced finding from this work was the discovery of the somatic mutation 
MYD88L265P, which was present in 90% of patients with WM. MYD88 serves as an 
adaptor molecule in TLR and IL1R signaling mediating IRAK4 and IRAK1 activation 
and down stream signaling through NFκB [70,111,112]. Mutations in MYD88 are 
significant given the importance of NFκB signaling in WM cell growth and survival [32]. 
We recently demonstrated that MYD88L265P can trigger NFκB signaling through an 
IRAK-independent pathway by direct interaction with BTK in WM cells, suggesting 
parallel pathways for NFκB activation [99]. In contrast to the findings by Ngo et al. who 
observed multiple MYD88 mutations (L265P, V217F, S219C, M232T, S243N, T294P) 
in ABC subtyped DLBCL patients, our findings were limited to the identification of 
L265P, and S219C as a subclonal event in one WM patient with a L265P mutation [70]. 
We also did not observe mutations in CARD11 in WM patients, demonstrating 
differences in potential oncogenic drivers and dependence on TLR signaling for WM 
versus ABC subtyped DLBCL. 
 
The next most common somatic variant by WGS after MYD88L265P was in CXCR4, 
present in 29% of the patients. The mutations identified in WM tumor cells recapitulated 
those found in the germline of patients with WHIM syndrome. To our knowledge, this is 
the first time WHIM-like mutations have been identified as somatic mutations in any 
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human cancer. In WHIM syndrome, loss of regulatory serines in the C-terminal tail of 
CXCR4 is known to impair receptor internalization, thereby prolonging G protein and β-
arrestin signaling [78]. The presence of CXCR4 mutations may also offer a targeted 
approach to therapy of WM by use of CXCR4 antagonists given their successful 
employment in the treatment of WHIM syndrome patients [113]. Several antagonists to 
CXCR4 have been developed and are in clinical trials including plerixafor, BMS-936564, 
AMD-070, and TG-0054, and warrant investigation alone and/or in combination in WM 
patients [114–117]. 
 
While most WM cases in our series did not have mutations in CXCR4, it is possible that 
CXCR4 signaling may still be critical for many of these patients and offers an 
opportunity for targeted therapy with CXCR4 antagonists [75]. Copy loss of RGS17 that 
was observed in 5 of 10 (50%) of patients in this series may also affect this pathway. 
CXCR4 signals downstream through Gαi G proteins increasing phosphorylated AKT 
levels and promoting cell survival whereas RGS17 inhibits Giα G proteins by promoting 
GTP hydrolysis [118,119]. In an analogous case, RGS17 inactivation was observed in 
ovarian cancer affecting Giα GPCR downstream signaling in response to lysophosphatidic 
acid [118]. 
 
The other major pathway identified in this study was the loss of the chromatin 
remodeling proteins, ARID1A and ARID1B [120]. ARID1A was the third most common 
SNV variant target in WM, with 5/30 (17%) of patients having validated nonsense or 
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frame shift mutations. In one patient, a mutation in ARID1A (Y551 frameshift) was 
homozygous as a result of an aUPD, whereas in another patient a nonsense mutation 
(Q2037X) was opposite CNA loss resulting in biallelic inactivation (Table 2). Loss of the 
alternate family member ARID1B was present in 7/10 (70%) of the paired patient 
samples making it a more frequent 6q target than either PRDM1 or TNFAIP3 (5/10; 50% 
for both) [120]. One potential target for this pathway is the B-cell development regulator 
EBF1 which itself was affected by CNA deletions in 4/10 (40%) patients [121,122]. Both 
ARID1A and ARID1B are members of the SWI/SNF family of proteins which are known 
to be mutated in other neoplastic malignancies wherein they are thought to exert their 
effects via TP53 and CDKN1A regulation [123–125]. TP53 itself was mutated in 2/30 
(7%) of the sequenced genomes including one case of biallelic mutation. PRDM2 and 
TOP1 both participate in TP53 related signaling and were deleted in 8/10 (80%; 28/30 in 
validation) and 6/10 (60%) of patients respectively [126,127]. Taken together, these 
findings imply that multiple mutations exist in the genome of WM patients which 
dysregulate the DNA damage response.  
 
Loss of additional cancer associated genes was observed including ETV6, which was 
deleted in 6/10 (60%) of the samples analyzed. Deletions of ETV6 have been observed in 
acute lymphoblastic leukemia (ALL), acute myeloid leukemia, and myelodysplastic 
syndromes [128–130]. ETV6 is a member of the ETS transcription factor family and acts 
primarily as a transcriptional repressor involved in hematopoiesis and functions as a 
tumor suppressor in myeloid leukemias [131]. FOXO3, which was deleted in 6/10 (60%) 
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of patients, has been shown to negatively regulate growth and survival in mantle cell 
lymphoma, B-CLL, and natural killer cell neoplasms [132–134]. In B-CLL, 
phosphorylation of FOXO3 by AKT down stream of SDF-1α and CXCR4 prevents 
FOXO3 nuclear translocation and signaling [133]. Upon nuclear translocation, FOXO3 
can induce transcription of BTG1 which was deleted in 9/10 (90%; 26/30 in validation) 
paired patients [135]. While FOXO3 (6q21) was not explicitly validated, 6q deletions 
were significantly less common in CXCR4 mutated patients and there was a trend for 
fewer BTG1 deletions as well. BTG1 is a nuclear co-activator that modulates 
transcription, a member of the anti-proliferative TOB/BTG protein family, and was 
recently demonstrated to be recurrently mutated in several studies of DLBCL 
[72,136,137]. Small deletions affecting BTG1 have been reported in up to 12% of the B-
cell precursor subtype of ALL (BCP-ALL) [130,138,139]. BTG1 deletions in BCP-ALL 
were noted to coincide with deletions in ETV6 and EBF1 both of which were recurrently 
deleted in our study and suggests that these events may be functionally related [139]. 
Preclinical studies of BTG1 in ALL have shown that loss of BTG1 is associated with 
glucocorticoid resistance. These findings may explain the poor responses observed to 
single agent steroids in WM, and warrant further investigation of BTG1 loss in treatment 
outcomes in patients undergoing glucocorticoid inclusive therapy [4,140]. Finally, 
biallelic loss of RNF213 resulting from two distinct t(2;17)s was observed in 1 of 10 
paired patients, and represents an interesting finding since RNF213 is a fusion partner of 
ALK and MYC in acute anaplastic large cell lymphoma. In the WM patient with the 
t(2;17) translocation, RNF213 was translocated to the intergenic space indicating that the 
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loss of RNF213 itself may play an important role in oncogenesis [141,142]. It is 
important to note that most CNAs were consistent with heterozygous loss whereas 
classical tumor suppressors require biallelic loss for oncogenesis. However, these losses 
could lead to pathway modulation due to altered protein levels or creation of dominant 
negatives by partial gene loss. 
 
Many of the mutations identified in this study impact NFκB signaling distal to the 
TLR4/MYD88 pathway. MYBBP1A, mutated in 2/30 (7%) patients, is thought to inhibit 
NFκB activity by repressing RELA [143]. Copy loss of HIVEP2 (8/10; 80%; 23/30 in 
validation) and TNFAIP3 in 5/10 (50%) of the paired patients is of interest since their 
loss results in the removal of NFκB negative regulators in WM [31,144]. Chromosome 
6q is often deleted in WM patients, and the apparent loss of HIVEP2 in 6q intact patients 
is particularly compelling for a role of this gene in the pathogenesis of WM. Likewise, 
BIRC3 loss in 4/10 (40%) of patients is associated with splenic MZL and can increase 
activation of non-canonical NFκB signaling [145]. Interestingly, both of BIRC3’s partner 
proteins, TRAF2 and TRAF3, which regulate non-canonical NFκB signaling were each 
found to be mutated in 1/30 (3%) patients. Biallelic loss of TRAF3 has been reported by 
Braggio et al in WM patients [31]. These findings may provide an impetus for studying 
non-canonical NFκB signaling in WM. 
 
The loss in 7/10 (70%; 18/30 in validation) paired patients of LYN, a kinase that plays a 
regulatory role for B-cell receptor (BCR) signaling along with mutations in CD79B 
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(2/30; 7%) indicates a possible role for BCR signaling in this disease [146–148]. The loss 
of IBTK in 4/10 (40%) of patients, and the interaction between activated MYD88 and 
BTK, raises the possibility for BTK mediated cross-talk with the TLR/MYD88 pathway 
wherein BTK plays an important role in NFκB activation [99,149–151]. Moreover, 
CBLB, a gene disrupted in chronic myelogenous leukemia and lost in 5/10 (50%) of the 
paired patients has been shown to inhibit the TLR4 response during inflammation by 
controlling TRL4 and MYD88 association, and subsequent NFκB activation [152,153]. 
However, there is still limited data regarding the structure of the MYD88L265P mutant 
protein. Signaling pathways that are well documented in the wild type setting will need to 
be carefully re-examined to clarify the contribution of the L265P mutation to downstream 
MYD88 signaling.  
 
The WGS studies in WM patients have therefore identified mutations in genes involving 
TLR, NFκB, and CXCR4 signaling, chromatin remodeling, and cell cycle regulation. 
These findings may denote a multistep process for WM evolution from IgM MGUS to 
asymptomatic and symptomatic WM, which invariably will require comparative, and 
even prospective longitudinal sequencing studies. These efforts are particularly warranted 
since the principal mutation (MYD88L265P) identified in these studies is also present in 
50-80% of IgM MGUS patients using AS-PCR, signifying its role as an early oncogenic 
event [154–156]. Other mutations therefore are likely to be acquired in the evolution of 
MGUS to symptomatic WM, and may offer opportunity to identify those patients at high 
risk for disease evolution. Lastly, these studies have also identified novel targets for a 
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rational approach to WM treatment, including potentially the use of inhibitors targeting 
TLR and CXCR4 signaling. 
 
Section Two – MYD88 and CXCR4  
Although there have been a number of previous studies documenting the presence of 
MYD88L265P in CLL, DLBCL, and other disorders, this study was the first to identify the 
MYD88L265P mutation in WM [70,137,157]. There have also been reports of high rates of 
MYD88L265P in primary central nervous system (CNS) lymphoma and immune privileged 
DLBCL [158,159]. This experience has been born out in CNS involved WM, known as 
Bing Neel syndrome, where it has been shown that AS-PCR MYD88L265P assays can be 
used to detect WM LPC in the spinal fluid ruling out secondary CNS malignancies [160]. 
In fact, many confirmatory studies of MYD88L265P mutation rates in WM and IgM 
MGUS from around the world using a variety of techniques have now been reported as 
seen in Table 9 [111,112,154–156,161–168]. 
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Table 9: MYD88L265P confirmatory studies in WM and IgM MGUS 
Detection techniques included, PCR, AS-PCR, Sanger sequencing, whole genome sequencing (WGS), whole exome 
sequencing (WES), and restriction fragment length polymorphism testing (RFLP) 
 
Although the clinical utility of this MYD88L265P in disease monitoring and response 
assessment will require validation in prospective studies, the AS-PCR assay can be 
employed to help distinguish WM from the closely related IgM MM and splenic MZL, 
especially in practices that are not specialized in rare NHL disease diagnosis. The 
availability of peripheral blood testing in untreated patients makes for easy outsourcing to 
specialized laboratories in settings where conducting the test locally is not feasible [169]. 
The discordance between the MYD88L265P PB and BM assays in the previously treated 
and untreated WM are difficult to interpret definitively given the differences in therapy, 
timing, and small number of samples available. CXCR4WHIM somatic mutations promote 
homing to the BM and therapeutic resistance. Given the importance of the BM 
microenvironment to WM cell growth and survival, one possible explanation is that 
METHOD TISSUE WM IGM MGUS 
Treon111  WGS/Sanger BM CD19+ 91% 10% 
Xu112 AS-PCR BM CD19+ 93% 54% 
Gachard154 PCR BM 70% 
Varettoni155 AS-PCR BM 100% 47% 
Landgren156 Sanger BM 54% 
Jiminez161 AS-PCR BM 86% 87% 
Poulain162 PCR BM CD19+ 80% 
Argentou163 PCR-RFLP BM 92% 100% (1/1) 
Willenbacher164 Sanger BM 86% 
Mori165 AS-PCR/RFLP BM 80% 
Ondrejka166 AS-PCR BM  100% 
Ansell167 WES/AS-PCR BM 97% 
Patkar168 AS-PCR BM 85% 
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therapy selects for non-circulating WM cells that have these CXCR4 mutations or have 
up-regulated adhesion molecules anchoring them in the BM [37,95,97].   
 
As the CXCR4WHIM mutations are the first to be described in oncology, little is known 
about their putative role in lymphoma pathogenesis. A recently published study 
confirmed many of our primary findings related to CXCR4 mutations in WM [170]. Our 
results also find support from prior work in WHIM syndrome, and CXCR4 dysregulation 
in other cancers where it is thought to play a role in tumor metastasis and cancer stem cell 
development [81,103,171]. In WM, BM homing and Gαi cross talk with the Toll-like 
receptors to mediate inflammatory signaling programs may be more relevant and explain 
why CXCR4WHIM mutations are found nearly exclusively in MYD88L265P patients 
[73,101]. Regardless, the clinical differences observed between patients with FS versus 
NS CXCR4 mutations in this study indicate that there are multiple pathways involved. 
While differences in β-arrestin signaling seem the likely culprit, differences in 
heterodimerization with CXCR7, or C-terminal ubiquitination may also play a role 
[78,103,172,173]. Further functional studies of FS and NS mutations are needed, 
especially in primary patient samples as genotype specific cooperating mutations may co-
evolve in the tumor generating misleading results if studied only in transduced cell lines. 
Expanded cohort studies of CXCR4WHIM WM patients are needed with more sensitive 
testing to study the clonal evolution of CXCR4 mutations relative to MYD88L265P over 
time so as to better understand their role in disease progression and therapeutic resistance. 	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Section Three – Study Limitations and Future Work 
Perhaps the most significant limitation in the WGS study was the 10ug DNA requirement 
for the next generation sequencing. Obtaining this quantity of DNA with enough reserve 
for confirmatory studies essentially dictated the eligible participants in the WGS cohort. 
In addition to our inability to control demographic bias, this requirement may have lead 
to subtle selection biases as well. Similar to how MYD88WT was associated with lower 
BM involvement, our ability to extract large quantities of WM LPCs from samples may 
select for or against a particular genotype. For example, one of the MYD88L265P 
confirmatory studies from Table 9 arrived at a 100% mutation rate when they imposed a 
minimum BM LPC involvement for study participation which may have effectively 
filtered out MYD88WT patients [155]. Another limitation was that this study examined 
only non-synonymous variants. Without additional data such as gene expression profiling 
or whole transcriptome sequencing, the potential impact of somatic mutations in introns 
or in intergenic space is very difficult to interpret.  
 
While the copy number analysis revealed many novel validated deletions in this cohort, 
the high concordance between samples suggests that there may be a mechanistic basis for 
some of these findings. BTG1, a gene deleted in 87% of WM patients in this study, is 
also deleted in acute lymphoblastic leukemia possibly due to RAG1/RAG2 off target 
recombination [139]. However, with 100Kb CNA windows, there is not sufficient 
resolution of the actual breakpoints to sequence across the deletion and validate such a 
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hypothesis. Development of improved algorithms focusing on increased resolution is 
currently underway. 
 
Despite their limitations, these studies described a host of novel recurrent mutations and 
greatly extended our understanding of WM pathogenesis. This included the identification 
of two highly recurrent driver mutations, MYD88L265P and CXCR4WHIM, which also serve 
as novel prognostic and predictive markers [99,174]. Although lack of paired sequencing 
in two thirds of the cohort significantly decreased the power to detect somatic mutations, 
future sequencing of the germline tissue of these patients will contribute to further 
decoding of the WM genomic landscape. Studies collecting paired WGS, gene 
expression, promoter methylation, and chromatin immunoprecipitation data are needed to 
better interpret the significance of these findings and translate such knowledge into 
improved therapeutics for the care of patients with this rare disease. 
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APPENDIX 1 – Whole Genome Sequencing Sanger Validation 
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APPENDIX 2 – Somatic and Unclassified Mutations in COSMIC Census Genes 
Gene Somatic Unpaired Total Chromosome Band 
MYD88 10 17 27 chr3 p22.2 
ARID1A 2 3 5 chr1 p36.11 
C15orf55 0 3 3 chr15 q14 
ROS1 0 3 3 chr6 q22.1 
BCL9 1 1 2 chr1 q21.2 
MLL3 1 1 2 chr7 q36.1 
MYH9 1 1 2 chr22 q12.3 
BRCA2 0 2 2 chr13 q13.1 
CDH11 0 2 2 chr16 q21 
CREB3L1 0 2 2 chr11 p11.2 
CYLD 0 2 2 chr16 q12.1 
EP300 0 2 2 chr22 q13.2 
KTN1 0 2 2 chr14 q22.3 
MLL2 0 2 2 chr12 q13.12 
MLLT6 0 2 2 chr17 q12 
MYST4 0 2 2 chr10 q22.2 
NUMA1 0 2 2 chr11 q13.4 
PER1 0 2 2 chr17 p13.1 
SRGAP3 0 2 2 chr3 p25.3 
TP53 0 2 2 chr17 p13.1 
IRF4 1 0 1 chr6 p25.3 
REL 1 0 1 chr2 p16.1 
RUNDC2A 1 0 1 chr16 p13.13 
SYK 1 0 1 chr9 q22.2 
WIF1 1 0 1 chr12 q14.3 
ATM 0 1 1 chr11 q22.3 
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ATRX 0 1 1 chrX q21.1 
BCL10 0 1 1 chr1 p22.3 
BCL2 0 1 1 chr18 q21.33 
BCL6 0 1 1 chr3 q27.3 
BCR 0 1 1 chr22 q11.23 
BUB1B 0 1 1 chr15 q15.1 
CBFB 0 1 1 chr16 q22.1 
CD79B 0 1 1 chr17 q23.3 
CHEK2 0 1 1 chr22 q12.1 
CIITA 0 1 1 chr16 p13.13 
ETV5 0 1 1 chr3 q27.2 
FGFR1 0 1 1 chr8 p11.23 
FGFR3 0 1 1 chr4 p16.3 
FOXL2 0 1 1 chr3 q22.3 
HIP1 0 1 1 chr7 q11.23 
HMGA1 0 1 1 chr6 p21.31 
IL7R 0 1 1 chr5 p13.2 
JAK2 0 1 1 chr9 p24.1 
JUN 0 1 1 chr1 p32.1 
KDM6A 0 1 1 chrX p11.3 
LCP1 0 1 1 chr13 q14.13 
MET 0 1 1 chr7 q31.2 
MKL1 0 1 1 chr22 q13.1 
MLL 0 1 1 chr11 q23.3 
MN1 0 1 1 chr22 q12.1 
MYB 0 1 1 chr6 q23.3 
NACA 0 1 1 chr12 q13.3 
NIN 0 1 1 chr14 q22.1 
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NTRK1 0 1 1 chr1 q23.1 
PAX5 0 1 1 chr9 p13.2 
PIM1 0 1 1 chr6 p21.2 
PMS1 0 1 1 chr2 q32.2 
PRCC 0 1 1 chr1 q23.1 
PRDM16 0 1 1 chr1 p36.32 
RANBP17 0 1 1 chr5 q35.1 
RPN1 0 1 1 chr3 q21.3 
RUNX1 0 1 1 chr21 q22.12 
SETD2 0 1 1 chr3 p21.31 
SMARCA4 0 1 1 chr19 p13.2 
SOX2 0 1 1 chr3 q26.33 
SUZ12 0 1 1 chr17 q11.2 
TCF7L2 0 1 1 chr10 q25.3 
TFRC 0 1 1 chr3 q29 
TNFRSF17 0 1 1 chr16 p13.13 
TSHR 0 1 1 chr14 q31.1 
WHSC1 0 1 1 chr4 p16.3 
XPC 0 1 1 chr3 p25.1 
ZNF384 0 1 1 chr12 p13.31 
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APPENDIX 3 – Statistically Significant Somatic Copy Number Alterations 
Chromosome Band Begin End Type Tally P-Value 
chr1 p36.33 571,368 671,368 del 10 00.00E+0 
chr1 p36.21 14,057,162 14,157,162 del 8 00.00E+0 
chr1 p34.2 40,878,082 40,978,082 del 7  1.52E-6 
chr1 p31.3 65,378,082 65,478,082 del 4 21.14E-4 
chr1 p31.3 66,778,082 66,878,082 del 8 00.00E+0 
chr1 NA 66,878,082 66,978,082 del 6  9.09E-6 
chr1 p12 118,163,906 118,263,906 del 4 21.14E-4 
chr1 q24.2 167,659,645 167,759,645 del 4 21.14E-4 
chr1 q25.2 178,859,645 178,959,645 del 6  9.09E-6 
chr1 q31.3 198,559,645 198,659,645 del 4 21.14E-4 
chr1 q31.3 198,659,645 198,759,645 del 8 00.00E+0 
chr2 p14 64,292,692 64,392,692 del 5  1.50E-4 
chr2 p14 64,392,692 64,492,692 del 7  1.52E-6 
chr2 p13.3 68,992,692 69,092,692 del 6  9.09E-6 
chr2 p11.2 89,168,206 89,268,206 del 10 00.00E+0 
chr2 p11.2 89,268,206 89,368,206 del 9 00.00E+0 
chr2 p11.2 89,368,206 89,468,206 del 8 00.00E+0 
chr2 p11.2 89,468,206 89,568,206 del 7  1.52E-6 
chr2 p11.2 89,568,206 89,668,206 del 4 21.14E-4 
chr2 p11.2 89,980,436 90,080,436 del 5  1.50E-4 
chr2 p11.2 90,180,436 90,280,436 del 6  9.09E-6 
chr2 q21.2 135,001,337 135,101,337 del 4 21.14E-4 
chr2 q22.1 136,901,337 137,001,337 del 7  1.52E-6 
chr2 q24.1 158,240,582 158,440,582 del 6  9.09E-6 
chr2 q24.3 165,640,582 165,740,582 del 4 21.14E-4 
chr2 q33.1 197,040,582 197,140,582 del 7  1.52E-6 
chr2 q33.1 198,040,582 198,140,582 del 5  1.50E-4 
chr2 q33.1 198,140,582 198,240,582 del 6  9.09E-6 
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chr3 p23 30,710,000 30,810,000 del 6  9.09E-6 
chr3 p22.3 31,910,000 32,010,000 del 5  1.50E-4 
chr3 p13 71,020,270 71,120,270 del 4 21.14E-4 
chr3 p13 71,120,270 71,220,270 del 7  1.52E-6 
chr3 p13 71,220,270 71,520,270 del 5  1.50E-4 
chr3 q12.3 101,554,854 101,654,854 del 5  1.50E-4 
chr3 q13.11 105,554,854 105,654,854 del 5  1.50E-4 
chr3 q13.31 114,154,854 114,254,854 del 4 21.14E-4 
chr3 q25.1 151,954,854 152,054,854 del 5  1.50E-4 
chr3 q25.1 152,054,854 152,154,854 del 4 21.14E-4 
chr3 q26.32 176,854,854 176,954,854 del 4 21.14E-4 
chr3 q27.3 186,754,854 186,854,854 del 6  9.09E-6 
chr3 q28 191,054,854 191,154,854 del 4 21.14E-4 
chr4 p14 40,190,638 40,290,638 del 5  1.50E-4 
chr4 q21.23 86,402,279 86,502,279 del 4 21.14E-4 
chr4 q21.23 86,502,279 86,702,279 del 5  1.50E-4 
chr4 q24 102,902,279 103,002,279 del 4 21.14E-4 
chr4 q31.3 153,402,279 153,502,279 del 5  1.50E-4 
chr4 q32.3 164,502,279 164,602,279 del 4 21.14E-4 
chr5 p15.2 14,160,000 14,260,000 del 4 21.14E-4 
chr5 q11.2 56,155,641 56,255,641 del 4 21.14E-4 
chr5 q14.3 88,155,641 88,255,641 del 4 21.14E-4 
chr5 q23.1 118,636,128 118,736,128 del 4 21.14E-4 
chr5 q23.3 130,536,128 130,636,128 del 4 21.14E-4 
chr5 q23.3 130,636,128 130,736,128 del 7  1.52E-6 
chr5 q31.1 130,736,128 130,836,128 del 6  9.09E-6 
chr5 q33.1 149,787,073 149,887,073 del 7  1.52E-6 
chr5 q33.3 158,338,727 158,538,727 del 4 21.14E-4 
chr6 p23 14,110,000 14,210,000 del 5  1.50E-4 
chr6 p21.32 32,610,000 32,710,000 del 7  1.52E-6 
chr6 q12 69,628,589 70,528,589 del 4 21.14E-4 
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chr6 q13 70,528,589 70,628,589 del 6  9.09E-6 
chr6 q13 70,628,589 74,228,589 del 4 21.14E-4 
chr6 q13 74,228,589 74,328,589 del 5  1.50E-4 
chr6 q13 74,328,589 76,328,589 del 4 21.14E-4 
chr6 q14.1 76,328,589 76,428,589 del 5  1.50E-4 
chr6 q14.1 76,428,589 78,028,589 del 4 21.14E-4 
chr6 q14.1 82,628,589 83,228,589 del 4 21.14E-4 
chr6 NA 83,428,589 83,928,589 del 4 21.14E-4 
chr6 q15 90,828,589 91,128,589 del 6  9.09E-6 
chr6 q16.2 99,880,543 100,080,543 del 4 21.14E-4 
chr6 q16.3 101,280,543 101,380,543 del 4 21.14E-4 
chr6 NA 101,680,543 105,580,543 del 4 21.14E-4 
chr6 q21 106,280,543 106,480,543 del 4 21.14E-4 
chr6 q21 106,480,543 106,580,543 del 5  1.50E-4 
chr6 q21 106,580,543 106,680,543 del 6  9.09E-6 
chr6 q21 106,680,543 106,980,543 del 4 21.14E-4 
chr6 q21 106,980,543 107,080,543 del 5  1.50E-4 
chr6 q21 107,080,543 107,180,543 del 6  9.09E-6 
chr6 q21 107,180,543 108,880,543 del 4 21.14E-4 
chr6 q21 108,880,543 108,980,543 del 6  9.09E-6 
chr6 q21 108,980,543 109,080,543 del 5  1.50E-4 
chr6 q21 109,080,543 110,080,543 del 4 21.14E-4 
chr6 q21 113,980,543 114,080,543 del 4 21.14E-4 
chr6 q22.31 119,580,543 119,780,543 del 5  1.50E-4 
chr6 q22.31 124,880,543 126,080,543 del 4 21.14E-4 
chr6 q22.32 126,080,543 126,180,543 del 5  1.50E-4 
chr6 q22.32 126,180,543 128,180,543 del 4 21.14E-4 
chr6 q23.2 132,880,543 133,480,543 del 4 21.14E-4 
chr6 NA 133,880,543 134,880,543 del 4 21.14E-4 
chr6 q23.2 134,880,543 136,580,543 del 5  1.50E-4 
chr6 q23.3 136,580,543 136,680,543 del 7  1.52E-6 
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chr6 q23.3 136,680,543 137,080,543 del 5  1.50E-4 
chr6 q23.3 137,080,543 137,180,543 del 6  9.09E-6 
chr6 q24.1 139,480,543 139,580,543 del 7  1.52E-6 
chr6 q24.1 139,580,543 141,880,543 del 5  1.50E-4 
chr6 q24.1 141,880,543 143,080,543 del 4 21.14E-4 
chr6 q24.2 143,080,543 143,180,543 del 5  1.50E-4 
chr6 q24.2 143,180,543 143,280,543 del 8 00.00E+0 
chr6 q24.2 143,280,543 143,380,543 del 6  9.09E-6 
chr6 q24.2 143,380,543 144,680,543 del 4 21.14E-4 
chr6 q24.2 144,680,543 144,780,543 del 7  1.52E-6 
chr6 q24.2 144,780,543 149,680,543 del 4 21.14E-4 
chr6 q25.1 149,680,543 149,880,543 del 5  1.50E-4 
chr6 q25.1 149,880,543 150,880,543 del 4 21.14E-4 
chr6 q25.1 150,880,543 150,980,543 del 7  1.52E-6 
chr6 q25.1 150,980,543 151,080,543 del 9 00.00E+0 
chr6 q25.1 151,080,543 151,180,543 del 7  1.52E-6 
chr6 q25.1 151,180,543 153,980,543 del 4 21.14E-4 
chr6 q25.2 154,480,543 157,080,543 del 4 21.14E-4 
chr6 q25.3 157,080,543 157,180,543 del 6  9.09E-6 
chr6 q25.3 157,180,543 157,480,543 del 7  1.52E-6 
chr6 q25.3 158,241,300 158,441,300 del 5  1.50E-4 
chr6 q25.3 159,141,300 159,241,300 del 6  9.09E-6 
chr6 q25.3 159,241,300 159,341,300 del 9 00.00E+0 
chr6 q25.3 159,341,300 159,441,300 del 4 21.14E-4 
chr6 q25.3 159,441,300 159,541,300 del 7  1.52E-6 
chr6 q27 167,541,300 167,641,300 del 5  1.50E-4 
chr7 p21.1 18,532,484 18,632,484 del 5  1.50E-4 
chr7 p21.1 18,632,484 18,732,484 del 4 21.14E-4 
chr7 p15.3 22,732,484 22,832,484 del 4 21.14E-4 
chr7 p14.1 38,332,484 38,432,484 amp 10 00.00E+0 
chr7 p11.2 55,560,631 55,660,631 del 6  9.09E-6 
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chr7 q22.3 104,656,043 104,756,043 del 7  1.52E-6 
chr7 q22.3 104,756,043 104,856,043 del 4 21.14E-4 
chr7 q32.3 130,604,523 130,704,523 del 7  1.52E-6 
chr7 q32.3 130,704,523 130,804,523 del 10 00.00E+0 
chr7 q32.3 130,804,523 130,904,523 del 7  1.52E-6 
chr7 q34 142,148,195 142,248,195 amp 6  9.09E-6 
chr7 q34 142,376,197 142,476,197 amp 10 00.00E+0 
chr7 q34 142,476,197 142,576,197 amp 9 00.00E+0 
chr8 p11.1 43,091,854 43,191,854 del 5  1.50E-4 
chr8 q12.1 56,785,599 56,985,599 del 7  1.52E-6 
chr8 q22.3 101,976,451 102,076,451 del 5  1.50E-4 
chr8 q24.13 125,676,451 125,776,451 del 4 21.14E-4 
chr9 p13.2 37,260,000 37,360,000 del 4 21.14E-4 
chr9 q34.11 132,728,796 132,828,796 del 7  1.52E-6 
chr9 q34.11 132,828,796 132,928,796 del 5  1.50E-4 
chr10 p14 11,610,000 11,710,000 del 7  1.52E-6 
chr10 q21.2 63,798,845 63,898,845 del 4 21.14E-4 
chr10 q21.3 64,998,845 65,098,845 del 7  1.52E-6 
chr11 p15.4 9,662,759 9,762,759 del 5  1.50E-4 
chr11 p13 35,162,759 35,262,759 del 7  1.52E-6 
chr11 q13.1 65,244,205 65,344,205 del 7  1.52E-6 
chr11 q14.1 82,724,695 82,824,695 del 6  9.09E-6 
chr11 q14.1 82,824,695 82,924,695 del 4 21.14E-4 
chr11 q21 95,988,378 96,088,378 del 4 21.14E-4 
chr11 q22.2 102,187,584 102,287,584 del 4 21.14E-4 
chr11 q24.3 128,287,584 128,387,584 del 5  1.50E-4 
chr11 q24.3 128,387,584 128,487,584 del 6  9.09E-6 
chr12 p13.31 9,889,876 9,989,876 del 7  1.52E-6 
chr12 p13.2 11,889,876 11,989,876 del 5  1.50E-4 
chr12 q21.33 90,006,694 90,106,694 del 5  1.50E-4 
chr12 q21.33 90,106,694 90,206,694 del 4 21.14E-4 
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chr12 q21.33 92,506,694 92,606,694 del 9 00.00E+0 
chr12 NA 92,606,694 92,706,694 del 4 21.14E-4 
chr13 q14.11 41,570,000 41,670,000 del 7  1.52E-6 
chr13 q14.2 50,670,000 50,770,000 del 5  1.50E-4 
chr13 q32.3 99,960,324 100,060,324 del 6  9.09E-6 
chr14 q11.2 21,750,000 21,850,000 del 4 21.14E-4 
chr14 q11.2 22,250,000 22,350,000 amp 4 21.14E-4 
chr14 q11.2 22,350,000 22,450,000 amp 5  1.50E-4 
chr14 q11.2 22,950,000 23,050,000 amp 10 00.00E+0 
chr14 q24.2 71,850,000 71,950,000 del 6  9.09E-6 
chr14 q32.33 106,350,000 106,650,000 del 10 00.00E+0 
chr14 q32.33 106,650,000 106,750,000 del 7  1.52E-6 
chr14 q32.33 106,750,000 106,850,000 del 6  9.09E-6 
chr14 q32.33 106,850,000 106,950,000 del 4 21.14E-4 
chr15 q25.3 85,984,473 86,084,473 del 6  9.09E-6 
chr15 q25.3 86,084,473 86,284,473 del 4 21.14E-4 
chr15 q26.1 93,484,473 93,584,473 del 5  1.50E-4 
chr16 q23.3 81,835,801 81,935,801 del 4 21.14E-4 
chr17 q12 37,975,848 38,075,848 del 4 21.14E-4 
chr17 q25.1 73,310,760 73,410,760 del 4 21.14E-4 
chr17 q25.3 76,710,760 76,810,760 del 8 00.00E+0 
chr17 q25.3 76,810,760 76,910,760 del 4 21.14E-4 
chr18 p11.32 2,660,000 2,760,000 del 6  9.09E-6 
chr18 p11.32 2,760,000 2,860,000 del 5  1.50E-4 
chr18 q21.2 52,959,136 53,159,136 del 6  9.09E-6 
chr18 q21.2 53,159,136 53,259,136 del 5  1.50E-4 
chr19 p13.11 18,387,198 18,487,198 del 6  9.09E-6 
chr20 q12 39,697,085 39,797,085 del 6  9.09E-6 
chr20 q13.12 46,097,085 46,197,085 del 5  1.50E-4 
chr20 q13.13 46,197,085 46,297,085 del 7  1.52E-6 
chr20 q13.13 49,197,085 49,297,085 del 6  9.09E-6 
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chr22 q11.22 23,259,431 23,359,431 del 4 21.14E-4 
chrX p11.4 40,998,256 41,098,256 del 5  1.50E-4 
chrX p11.4 41,598,256 41,698,256 del 5  1.50E-4 
chrX p11.23 46,798,256 46,898,256 del 5  1.50E-4 
chrX p11.23 46,898,256 46,998,256 del 4 21.14E-4 
chrX p11.23 48,798,256 48,898,256 del 4 21.14E-4 
chrX q22.3 106,953,692 107,053,692 del 5  1.50E-4 
chrX q25 123,113,235 123,213,235 del 4 21.14E-4 
chrY q11.221 15,548,578 15,648,578 del 4 21.14E-4 
chrY q11.223 23,369,679 23,469,679 del 7  1.52E-6 
chrY q11.223 23,469,679 23,569,679 del 6  9.09E-6 
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